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Abstract  
 
Dysregulation of apoptosis is a prime hallmark of leukemia. Therefore, drugs which 
restore the sensitivity of leukemic cells to apoptotic stimuli are promising candidates 
in the treatment of leukemia. The main objective of this dissertation was to examine 
the antileukemic effect of sanguinarine, in vitro, and to further examine the signaling 
mechanisms that may be involved. This study demonstrates that in human leukemic 
cells, sanguinarine activates a caspase-dependent apoptotic cell death pathway that 
is characterized by reactive oxygen species-dependent ceramide generation, and 
subsequent inhibition of Akt signaling pathway. In addition, sanguinarine also 
induces reactive oxygen species-dependent glutathione depletion and activation of 
extracellular signal-regulated kinase1/2. Moreover, inhibition of reactive oxygen 
species generation, using reactive oxygen species scavengers and antioxidants, 
significantly abrogates sanguinarine-induced ceramide generation, Akt 
dephosphorylation, extracellular signal-regulated kinase1/2 activation, and 
apoptosis. Sanguinarine-induced ceramide generation is mediated via reactive 
oxygen species-dependent activation of acid sphingomyelinase in Jurkat cells and 
inhibition of acid ceramidase and glucosylceramide synthase in both Jurkat and 
Molt-4 cells. Furthermore, the involvement of ceramide-activated protein 
phosphatase-1 in sanguinarine-induced Akt dephosphorylation and apoptosis is 
demonstrated. Altogether, this study underscores the critical role for reactive oxygen 
species-ceramide-Akt signaling pathway and reactive oxygen species-dependent 
extracellular signal-regulated kinase1/2 activation in the antileukemic action of 
sanguinarine. Understanding the molecular signaling mechanism of sanguinarine-
induced apoptosis undoubtedly should have a great impact on future sanguinarine-
based antileukemic drug development. 
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 )cibarA ni( tcartsbA dna eltiT
 
كعامل مضاد لسرطان الدم_ و إرتباطه بإشارات موت الخلايا ) eniraniugnas( مادة السانجوينارين دراسة
 )tkA( )_الأكيتيedimarec( المرتبط بجزيئات الأكسجين النشطة_السيراميد) sisotpopa( المبرمج
الدم. لذلك, فإن الأدوية التي تعيد ) هو السمة المميزة الرئيسية لسرطان sisotpopaالإخلال في موت الخلايا المبرمج (
) تكون مؤهلة للاستخدام كعلاج لسرطان sisotpopaاستجابة خلايا سرطان الدم     لاشارات موت الخلايا المبرمج (
 .                                                                )aimekuel( الدم
 ) كمضاد لسرطان الدم eniraniugnas( السانجوينارينتأثير مادة  الهدف الرئيسي من هذه الأطروحة هو دراسة
 .وإلى مواصلة دراسة آليات الإشارات التي يمكن أن تؤثر من خلالها هذه المادة , في المختبر)aimekuel(
يل ) تؤثر على خلايا سرطان الدم البشرية, عن طريق تفعeniraniugnas( السانجوينارينهذه الدراسة تبين أن مادة 
), yawhtap htaed llec citotpopa tnedneped-esapsac( الكاسبيس موت الخلايا المبرمج بالاعتماد على
-seiceps negyxo evitcaerو التي تتميز بتفعيل جزيئات الأكسجين النشطة المعتمدة على السراميد (
بالإضافة إلى ذلك, فإن مادة  .)tkA), و ينتج عنه تثبيط لإشارات الأكيتي (noitareneg edimarec tnedneped
) تقوم بتفعيل جزيئات الأكسجين النشطة المعتمدة على استنزاف الجلوتاثايون eniraniugnas( السانجوينارين
) و تفعيل اشارات الخلية المنظمة noitelped enoihtatulg tnedneped-seiceps negyxo evitcaer(
تثبيط توليد جزيئات الأكسجين النشطة بإستخدام السكافينجرز  و علاوة على ذلك, فإن).2/1esanikللكاينيز (
) و مضادات الأكسدة, أدى بشكل ملحوظ إلى إيقاف تولد السراميد المفعل عن طريق مادة sregnevacs(
 tkA), إزلة فسفرة الآكيتي (noitareneg edimarec decudni-eniraniugnasالسانجوينارين (
 detaluger-langis ralullecartxeشارات الخلية المنظمة من خلال الآكيتي (), تفعيل إnoitalyrohpsohped
) المفعل edimarec). إن تولد السيراميد (sisotpopa), و إلى موت الخلايا المبرمج (noitavitca 2/1esanik
لمعتمدة على ) يتم التحكم بها عن طريق جزيئات الأكسجين النشطة اeniraniugnaSعن طريق مادة السانجوينارين (
), و إلى تثبيط sllec takruJ) في خلايا الجيركيت (esanileymognihps dicaتنشيط حمض السفينجومايلينيس (
) في كل esahtnys edimareclysoculg) و الجلوكوسيراميد (esadimarec dicaإنتاج حمض السيراميديس (
 ).4-tloM( 4-) و مولتtakruJمن خلايا الجيركيت (
 nietorp detavitcaذلك, فإننا نظهر علاقة إرتباط بروتين السيراميد فوسفيتيس النشط (زيادة على 
 السانجوينارين) المفعلة عن طريق مادة noitalyrohpsohped tkA) في إزالة فسفرة الأكيتي (1-esatahpsohp
 ).sisotpopa) مع موت الخلايا المبرمج (eniraniugnas(
-لدور الحاسم للإشارات الخلوية لجزيئات الأكسجين النشطة المفعلة عن طريق السيراميدبالإجمال, هذه الدراسة تؤكد ا
) و جزيئات الأكسجين yawhtap gnilangis tkA-edimarec-seiceps negyxo evitcaerالأكيتي (
-seiceps negyxo evitcaerالنشطة المعتمدة على إشارات الخلوية السطحية المنظمة عن طريق تنشيط الكينيز (
 ) , كعوامل مضادة لسرطان الدم. noitavitca 2/1esanik detaluger-langis ralullecartxe tnedneped
بلا شك ),eniraniugnaS( السانجوينارينفي النهاية, إن فهم آلية الإشارات الجزيئية لموت الخلايا المبرمج بفعل مادة 
 ئم على هذه المادة في المستقبل .الدم القاأدوية سرطان سيكون له تأثير أكبر على تطوير 
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Chapter 1: Introduction 
1.1 Overview 
According to the National Cancer Institute (NCI), surveillance, epidemiology 
and end result (SEER) program report, it is estimated that during 2015, 
approximately 1.6 million new cancer cases will be diagnosed, and more than 580 
thousand people will die from cancer in the United States (Howlader et al., 2015). 
The cancer burden and related deaths is predicted to increase alarmingly by 2020, 
with approximately 15 million new cases and 12 million deaths globally. This is 
further expected to witness a catastrophic increase to 21 million new cancer cases 
and 13 million deaths by 2030 (Kanavos, 2006; "Cancer Facts and Figures 2015," 
2015). The burden will soon become a crisis as cancer incidence and death is 
rapidly and dramatically expanding in countries with less developed economies, 
where in the past, cancer related burden was significantly less (Kanavos, 2006). 
Clearly, cancer is an enormous global health burden, and should be effectively 
addressed with better therapeutic strategies. Currently, the most commonly used 
anticancer treatment involves chemotherapy, radiotherapy, and surgical resection. 
In this context, compounds derived from plants (phytochemicals) hold great potential 
for the development of next generation anticancer agents. 
Phytochemicals are non-nutritive components found in plants. They have 
long been used in the treatment of various ailments such as diabetes mellitus, 
cardiovascular disease, hypertension, and cancer. Earlier large-scale 
phytochemical-based clinical trials failed to demonstrate any positive clinical 
significance, and raised doubts over their use. Notably, lack of mechanism-based 
study design was considered as the major reason for the failure (K. W. Lee, Bode, & 
Dong, 2011). As a result, only very few phytochemical-based anticancer agents, 
such as vinblastine and vincristine, were available for the treatment of cancer (Bailly, 
2009).  
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During the 1980s, thanks to the advent of faster and better technologies, and 
the availability of large pool of mechanism-based preliminary studies, various plant-
based anticancer agents such as etoposide, vinorelbine, topotecan, teniposide, 
paclitaxel, and docetaxel were approved for the treatment of a number of different 
malignancies (Bailly, 2009). However, during the late 1990s, with the discovery of 
receptor specific anticancer agents, such as imatinib and rituximab, the cancer 
research focus shifted from natural products to synthetic small molecules. As a 
result, no phytochemical-based anticancer agent was approved during the years 
1997-2006 (Bailly, 2009). However, cancer being a heterogeneous disease driven 
by multiple signaling pathways, receptor specific anticancer agents have not been 
successful in a number of different cancers (Bailly, 2009). Consequently, interest in 
phytochemicals has renewed among cancer biologists and the pharmaceutical 
industry all over the world. Currently, over 60% of the clinically approved anticancer 
agents are either directly isolated from natural sources, or are modified from natural 
lead molecules (da Rocha, Lopes, & Schwartsmann, 2001). In addition, a large 
number of promising candidates are presently in clinical trial or in the development 
pipeline. Therefore, natural products are moving to be one of the most successful 
strategy for the discovery of new medicines. 
Considering their importance, NCI has funded and initiated a major 
screening program for antitumor activity from natural resources. By conducting a 
random screening, NCI has determined that more than 1000 different 
phytochemicals possess potent anticancer activities. Some of the most successful 
anticancer agents currently being used have been identified as a result of this 
screening program (K. W. Lee et al., 2011; Surh, 2003). Of the 250,000 plant 
species available, less than 10% have been tested for biological activities, and 
among them only a few have gone through extensive high-throughput screening 
process (Harvey, 2000). This indicates that there is a large untapped source of 
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phytochemical-based anticancer agents remaining to be discovered. With 
improvement in the techniques required for natural product isolation and biological 
testing, and better opportunity to explore previously inaccessible sources of natural 
products, it is crucial to carry out more rigorous research to identify promising 
anticancer candidates from natural sources. 
 Various advantages can be attributed to the study of phytochemicals in 
cancer therapy: (1) cancer is a heterogeneous disease characterized by extremely 
complex network of signaling interactions. Therefore, use of a single receptor 
specific anticancer agent based on lock-and-key model might not be successful in 
most cases. Phytochemicals usually have complex structures; therefore, they can 
act on a number of different targets with relatively low specificity. For example, 
curcumin was shown to induce apoptosis in human non-small cell lung cancer via 
modulation of multiple signaling pathways, leading to the induction of intrinsic-, 
extrinsic- and endoplasmic reticulum (ER) stress-mediated apoptosis (S. H. Wu et 
al., 2010). (2) Phytochemicals can be used as an additive or a synergistic agent 
together with conventional chemotherapeutic agents (combinatorial therapy), so as 
to reduce the dose and, therefore, increase the sensitivity and lower the potential for 
adverse drug reactions. For example, curcumin has been shown to inhibit multidrug 
resistant protein known as P-glycoprotein (P-gp), thereby promoting the sensitivity of 
vinblastine in multidrug resistant human cervical carcinoma cell line (Anuchapreeda, 
Leechanachai, Smith, Ambudkar, & Limtrakul, 2002). (3) Phytochemicals provide 
the best source for lead moieties, which can be subjected to structural modifications 
for the development of improved anticancer agents. For example, vinflunine, a 
modified form of vinblastine, is more efficacious than vinblastine (Kruczynski et al., 
2002).  
In summary, the immense potential of phytochemicals can serve as an 
excellent source for the development of novel antitumor agents. Therefore, it is 
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worthwhile to systematically investigate the anticancer potential of various 
phytochemicals. Such investigations can provide a scientific basis for designing 
targeted animal and human studies aimed at developing safe and efficacious 
anticancer therapy. 
1.2 Problem statement 
Leukemia is the most common type of childhood cancer in most parts of the 
world (Gilliland & Tallman, 2002; Harned & Gaynon, 2008; Vandenbriele, Dierickx, 
Amant, & Delforge, 2010). The estimated leukemia-related death in 2008 was 
around 250,000 globally ("Global Cancer Facts and Figures," 2011). The overall 
incidence of leukemia in the developed countries has been increasing since the last 
few decades ("Global Cancer Facts and Figures," 2011; Shah & Coleman, 2007). 
According to Heath Authority of Abu Dhabi (HAAD), leukemia is the most common 
type of cancer among males and the second most common type of cancer among 
females in Abu Dhabi ("Cancer in Abu Dhabi," 2011). Majority of children and 80% 
of children with cancer live in the developing countries (Pisani & Hery, 2006). 
Moreover, mortality trends of childhood cancers in developing countries are mostly 
underreported (Howard et al., 2008). Acute lymphoblastic leukemia (ALL) is the 
most common type of leukemia identified in children, accounting for 80% of the total 
leukemic cases (Morais et al., 2014). Most of the currently available chemotherapy 
regimens for ALL, or leukemia in general, are very intensive and can lead to severe 
systemic toxicities (Grigoropoulos, Petter, Van't Veer, Scott, & Follows, 2013). This 
signifies the importance of identifying novel nature-based therapeutic agents that 
can target and treat leukemia with least toxicity profile. Sanguinarine (SNG) is a 
benzophenanthridine alkaloid that has been shown to inhibit proliferation, and 
induce programmed cell death in various human cancer cell lines (Choi, Kim, Lee, & 
Choi, 2008; Dong et al., 2013; S. Gu et al., 2015; Hammerová, Uldrijan, Táborská, & 
Slaninová, 2011; Jang et al., 2009; Kalogris et al., 2014; S. Kim et al., 2008; Rosen 
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et al., 2015). It has been reported that SNG has a more profound cytotoxic effects 
against tumor cells when compared to normal cells (Ahmad, Gupta, Husain, 
Heiskanen, & Mukhtar, 2000; Kaminskyy, Lin, Filyak, & Stoika, 2008; Sun et al., 
2010). This preferential selectivity of SNG makes it a ‘druggable’ moiety in the 
treatment of cancer. This research was focused on elucidating the molecular 
signaling mechanism of anti-leukemic potential of SNG.  
1.3 Objective 
The ultimate goal of this research was identification of the role and 
mechanism of SNG-induced inhibition of proliferation of human leukemic cells. Such 
an understanding should provide a basis for designing novel therapeutic approaches 
to combat leukemia. The overall objectives of this study can be broadly broken down 
within the following five specific aims: 
1. To determine the intracellular mechanisms by which SNG inhibits proliferation 
and induces death in human leukemic cells.  
2. To investigate the role of reactive oxygen species (ROS) generation in SNG-
induced death in human leukemic cells. 
3. To elucidate the role of the tumor suppressor lipid, ceramide, in SNG-induced 
cell death. 
4. To examine the role of Akt, also known as protein kinase B (PKB), in SNG-
induced leukemic cell death.   
5. To delineate the involvement of mitogen activated protein kinases (MAPKs) in 
SNG-induced cell death. 
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Chapter 2: Review of literature 
2.1 Leukemia 
2.1.1 Overview of leukemia 
Leukemia constitutes a group of cancers that arise from malignant 
transformation of blood and blood forming organs (Grigoropoulos et al., 2013). 
According to recent SEER statistics, approximately 1.5% of United States men and 
women will be diagnosed with leukemia at some point during their lifetime (Howlader 
et al., 2015). In 2012, there were approximately 310,000 reported cases of leukemia 
in the United States (Howlader et al., 2015). Over the past 10 years, there has been 
a gradual, but significant, increase in the incidence of leukemia in the United States, 
with an estimated rate of approximately 54,000 new cases and 24,000 deaths in 
2015 (Howlader et al., 2015). Moreover, according to HAAD surveillance section 
report, leukemia is the first and second most common type of cancer among Abu 
Dhabi male and female population, respectively ("Cancer in Abu Dhabi," 2011).   
Leukemia can be classified in several ways. Based on the type of white 
blood cells involved, leukemia may be myelogenous or lymphocytic. Lymphocytic 
leukemia refers to cancer of the marrow cells which normally produce immune 
system cells, whereas, myelogenous leukemia is cancer of granulocytes or 
monocytes. Leukemia is also classified as acute and chronic on the basis of cell 
maturity. In acute leukemia, cells are immature blast cells, whereas, in chronic 
leukemia cells are more mature and functionally differentiated. Therefore, generally 
leukemia is classified as (1) acute lymphocytic leukemia (ALL), (2) chronic 
lymphocytic leukemia (CLL), (3) acute myelogenous leukemia (AML), and (4) 
chronic myelogenous leukemia (CML).  
Acute lymphoblastic leukemia is a malignant proliferation of lymphoid 
precursor cells in the bone marrow, blood, and extramedullary sites. It is the most 
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common type of leukemia identified in children and it accounts for 80% of the total 
leukemic cases (Morais et al., 2014). Additionally, ALL also accounts for a 
significant number of adult leukemia cases as well. Basically, a bimodal age 
distribution of ALL can be seen, with the first peak between 4-10 years, and a 
second peak at about 50 years (Gilliland & Tallman, 2002; Shah & Coleman, 2007). 
According to recent SEER report, there were an estimated 75,000 ALL cases in the 
United States in 2012 (Howlader et al., 2015). Over the past 10 years, the rate of 
ALL have been gradually rising on an average of 0.6% each year (Howlader et al., 
2015). The incidence of leukemia in general is steadily increasing in other 
developed countries as well ("Global Cancer Facts and Figures," 2011; Shah & 
Coleman, 2007). Majority of children and 80% of children with cancer live in the 
developing countries. However, there are no reliable population level data available 
concerninghe incidence and survival of leukemia patients (Howard et al., 2008; 
Pisani & Hery, 2006). 
2.1.2 Standard treatment of leukemia 
Advances in cytogenetic and molecular analyses have significantly improved 
our understanding of the molecular basis of leukemia. As a result, different 
therapeutically important subtypes of ALL have been identified, and treatment is 
more directed towards a genetically different subset of leukemia (Bhojwani, Howard, 
& Pui, 2009). In addition, results from a number of clinical trials have led to the 
development of chemotherapeutic regimens composed of multidrug combinations, 
and intensification of their dose and/or treatment duration (Carroll & Raetz, 2012). 
Altogether, these factors contributed to considerable improvement in the treatment 
of ALL, or leukemia in general. Depending on the cytogenetic characteristics, risk of 
relapse, and age of patients, a number of different treatment protocols have been 
employed for the management of ALL. Most of the treatment protocols are 
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traditionally divided into three different phases, namely remission induction, 
consolidation, and maintenance (Carroll & Raetz, 2012).  
Remission induction therapy is usually carried out for a period of 4-6 weeks 
to enable rapid reduction in vast amount of leukemic cells. The mainstay of induction 
regimen usually include vincristine, a corticosteroid (prednisone or dexamethasone), 
L-asparginase, and an anthracycline (Inaba, Greaves, & Mullighan, 2013; Pui, 
2010). Patients at high- or very high-risk, in addition may receive cyclophosphamide 
(Inaba et al., 2013; Pui, 2010). If the biological and clinical features of leukemia are 
more lucid, additional drugs can be considered for the remission induction of 
different subsets of ALL. For example, patient with Philadelphia chromosome-
positive ALL may benefit from addition of tyrosine kinase inhibitor imatinib to 
conventional chemotherapeutic regimen (Schultz et al., 2009). Similarly, infants with 
mixed lineage leukemia rearranged ALL, having increased expression of Fms-like 
tyrosine kinase 3 (FLT3), may require inclusion of FLT3 inhibitor lestaurtinib (P. 
Brown, Levis, McIntyre, Griesemer, & Small, 2006). Consolidation is usually carried 
out for a period of 20-30 weeks with an aim to eradicate any residual leukemic cells. 
Antimetabolites such as 6-mercaptopurine and methotrexate are the cornerstones of 
consolidation therapy (Inaba et al., 2013; Pui, 2010). Other commonly used drugs 
are vincristine and L-asparginase (high-dose). Maintenance therapy typically lasts 2-
3 years and comprises of daily dosage of 6-mercaptopurine, weekly methotrexate, 
and with or without monthly pulses of vincristine and prednisolone. Patients with 
Philadelphia chromosome-positive ALL may require addition of imatinib to this 
regimen (Inaba et al., 2013; Pui, 2010).  
Control of central nervous system (CNS) relapse remains as the major 
therapeutic challenge in the successful treatment of leukemia. Standard prophylaxis 
for CNS relapse involves triple-drug intrathecal chemotherapy with methotrexate, 
hydrocortisone, and high-dose of cytarabine (Inaba et al., 2013; Pui, 2010). Some of 
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the leukemic patients are also treated with allogenic stem cell transplantation (SCT). 
Treatment with SCT along with chemotherapy was demonstrated to be more 
beneficial than treatment with chemotherapy alone (Aricò et al., 2000). 
2.1.3 Complications associated with standard chemotherapy 
Although, leukemia therapy has witnessed some improvement at least in 
some subgroups of ALL, however, treatment results in significant amount of short- 
and long-term undesired consequences. For examples, glucocorticoids are 
associated with short term complications such as myopathy, behavioral problem, 
hyperglycemia and long-term complications such as osteonecrosis. Anthracyclines 
can cause severe cardiotoxicity. It is demonstrated that children treated with 
anthracyclines are at higher risk of developing late-onset cardiac arrest (Carroll & 
Raetz, 2012; D. S. Ziegler, Dalla Pozza, Waters, & Marshall, 2005). Methotrexate is 
responsible for renal and neurotoxicity, whilst, high-dose of cytarabine is associated 
with hepatotoxicity and cerebellar dysfunction (Fullmer, O'Brien, Kantarjian, & 
Jabbour, 2009). Hypersensitivity to L-asparginase is also a common concern 
(Asselin & Fisher, 2014). Additionally, SCT is associated with high rate of acute 
transplant related mortality. Therefore, SCT is limited to high-risk patients or patients 
with very higher prospect of relapse. 
2.1.4 Need for further improvement in antileukemic therapy 
Significant improvement in treatment of childhood ALL, or leukemia in 
general, has been achieved during the past few decades. However, infants less than 
1 year of age at diagnosis and adults are the exception to this improvement 
(Kotecha, Gottardo, Kees, & Cole, 2014; Narayanan & Shami, 2012). Moreover, 
about 20% of children treated with current chemotherapeutic regimes still relapse 
(D. S. Ziegler et al., 2005). Additionally, some survivors face an uncertain future of 
treatment related short- and long-term morbidity. To address these challenges, the 
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current therapeutic regimens are substantially modified to improve survival. 
However, despite these modifications, no definite advancement in survival was 
observed in most of these leukemia over the past two decades. Moreover, we are 
approaching the limit to which currently available chemotherapy can be further 
intensified with limited toxicity (Kotecha et al., 2014). Currently, more than 100 
clinical trials are underway focused on curing relapsed or refractory leukemia, as 
well as, the reduction of short- and long-term morbidity associated with treatment 
("NCI supported clinical trials," 2015). Therefore, there is a compelling rationale to 
discover and incorporate novel and promising drug candidates for the treatment of 
ALL and leukemia in general. To achieve this goal, there is a need for increased 
focus on better understanding the molecular signaling mechanisms of the novel 
antileukemic agents. Recently, phytochemicals have taken center stage as 
compounds with potential anticancer properties. Delineating the molecular 
mechanism of action and their anticancer potential will undoubtedly lead to novel 
antileukemic agents with improved outcomes in resistant and relapsed ALL patients. 
2.2 Apoptosis 
2.2.1 Apoptosis as a tumor suppressive mechanism 
Apoptosis, also known as type I programmed cell death, plays an important 
role in the maintenance of tissue homeostasis by eliminating harmful or unwanted 
cells. Defective apoptosis (increased or decreased) is implicated in various diseases 
such as diabetes mellitus, Alzheimer’s disease, and cancer. Evading apoptosis is 
one of the major hallmarks of cancer progression and resistance to chemotherapy. 
This has provided the necessary encouragement for exploiting a variety of 
therapeutic approaches that restores apoptosis either via inhibiting anti-apoptotic 
cellular machineries or reactivating pro-apoptotic components. 
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2.2.2 Morphological and biochemical features of apoptosis 
The process of apoptosis is characterized by a series of morphological changes and 
biochemical events. Some of the important morphological hallmarks of apoptosis are 
cellular shrinkage and detachment, chromatin condensation, membrane blebbing, 
and formation of small compact fragments known as apoptotic bodies (Fischer, 
Jänicke, & Schulze-Osthoff, 2003). Most of these morphological changes are 
mediated via proteolytic modification of a number of key proteins involved in 
cytoskeletal regulation and cellular organization. Proteolysis may be mediated by a 
unique family of cysteine-dependent aspartate-directed proteases known as 
caspases. However, caspase–independent mechanisms have also been implicated 
in this. For instance, caspase-mediated cleavage of P21 protein (Cdc42/Rac)-
activated kinase 2 (PAK2), gelsolin, and rho-associated coiled-coil-containing 
protein kinase I (ROCK I) are involved in the apoptotic membrane blebbing. 
Alternatively, membrane blebbing can be triggered by death-associated protein 
kinase (DAPK) via caspase-independent mechanism (Fischer et al., 2003; U. Ziegler 
& Groscurth, 2004). Moreover, caspase-dependent cleavage of acinus contributes 
to chromatin condensation, while cleavage of focal adhesion kinase (FAK) and 
paxillin induces cellular shrinkage and detachment (Fischer et al., 2003; U. Ziegler & 
Groscurth, 2004). 
The most important biochemical feature of apoptosis is activation of caspase 
signaling cascade itself. Most of the biochemical features of apoptosis are facilitated 
as a result of caspase activation. For example, caspase-3 and -7 mediate the 
cleavage of DNA repair protein Poly (ADP-ribose) polymerase-1 (PARP), leading to 
its inactivation (Fischer et al., 2003; Saraste & Pulkki, 2000). Cleavage of PARP is a 
hallmark of caspase-dependent apoptosis in most cases. Another important protein 
cleaved by caspases is inhibitor of caspase-activated DNase (ICAD). Caspase-
mediated cleavage of ICAD releases caspase activated DNase (CAD) from the hold 
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of ICAD, and induces DNA fragmentation. This DNA fragmentation can also be 
mediated by apoptosis inducing factor (AIF) and endonuclease G (EndoG) via 
caspase-independent mechanism (Fischer et al., 2003; Saraste & Pulkki, 2000). 
Another key biochemical feature of cells undergoing apoptosis is phosphatidylserine 
flipping from the inner leaflet to the outer leaflet of plasma membrane. Both 
caspase-dependent and -independent mechanisms are responsible for this process 
(Fischer et al., 2003; Saraste & Pulkki, 2000). 
2.2.3 Mechanisms of apoptosis 
 Apoptosis may be manifested via extrinsic death receptor mechanism 
and/or intrinsic mitochondrial mechanism (Fig. 2.1) (Galadari, Rahman, 
Pallichankandy, Galadari, & Thayyullathil, 2013; Galadari, Rahman, Pallichankandy, 
& Thayyullathil, 2015). 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Mechanism of apoptosis. Major regulators involved in intrinsic and 
extrinsic pathway of apoptosis is illustrated. 
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The extrinsic pathway begins outside the cell with the binding of death 
ligands, such as tumor necrosis factor-α (TNF-α) and Fas ligand (FasL), to their 
respective cell-surface death receptors such as TNF receptor (TNFR) and Fas 
receptor (FasR). The ligand-receptor interaction recruits adaptor protein (FADD for 
the FasR and TRADD for the TNFR) and procaspase dimer (mostly procaspase-8), 
leading to death-inducing signaling complex (DISC) formation and subsequent 
activation of caspase cascade and apoptosis (Fig. 2.1) (Galadari et al., 2013; 
Galadari et al., 2015).  
The intrinsic mitochondrial pathway is initiated within the cell in response to 
wide range of death stimuli. Regardless of the stimuli, mitochondrial membrane 
permeability is increased, and pro-apoptotic factors such as cytochrome-c (Cyt-c), 
AIF, EndoG, and second mitochondria-derived activator of caspases/direct IAP 
binding protein with low PI (Smac/DIABLO), etc., are released from the mitochondria 
through the permeability transition pore (PTP). Cyt-c complexes with the apoptotic 
protease activating factor 1 (Apaf-1), procaspase oligomers (mostly procaspase-9) 
and ATP, thereby, forming an entity called apoptosome (Fig. 2.1). In turn, the 
apoptosome once formed leads to the activation of caspase signaling cascade and 
induction of apoptosis (Galadari et al., 2013; Galadari et al., 2015). Alternatively, AIF 
and EndoG may translocate to the nucleus where they activate chromatin 
condensation and large scale DNA fragmentation in a caspase-independent 
manner. Smac/DIABLO neutralizes the anti-apoptotic functions of inhibitors of 
apoptosis proteins (IAP), hence, allowing the caspase activation and execution of 
apoptosis (Fig. 2.1) (Galadari et al., 2013; Galadari et al., 2015; Martinez-Ruiz, 
Maldonado, Ceballos-Cancino, Grajeda, & Melendez-Zajgla, 2008). 
2.2.4 Major regulators of apoptosis 
Caspases: These are unique family of proteases that initiate and execute the 
process of apoptosis. Caspases are generally divided into two classes: the initiator 
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caspases (caspase-2, -8, -9, -10, and -11) and the effector caspases (caspases-3, -
6, and -7). The two major mechanism of caspase activation are recruitment 
activation and transactivation. In recruitment activation, initiator procaspases such 
as procaspase-8 and procaspase-9 are recruited to the DISC and apoptosome 
complexes, respectively. The dimerization or oligomerization of the procaspases 
mediates proximity-induced autocatalytic cleavage and activation of caspases. In 
the transactivation mechanism, the effector procaspases, such as procaspase-3 and 
-7, are cleaved and activated by initiator caspases or other proteases. Following its 
activation, caspases propagate apoptotic signal via proteolysis of targets involved in 
the regulation of cell morphology and survival (Galadari et al., 2013; Galadari et al., 
2015).  
B-cell lymphoma-2 proteins: The intrinsic pathway of apoptosis is regulated by a 
group of proteins belonging to the B-cell lymphoma-2 (Bcl-2) family. There are two 
main groups of Bcl-2 proteins, namely the pro-apoptotic proteins (e.g. Bad, Bid, Bax, 
Bak, Bcl-Xs, Bim, etc.) and the anti-apoptotic proteins (e.g. Bcl-2, Bcl-xL, Mcl-1, 
etc.). The anti-apoptotic proteins reduce apoptosis by blocking the mitochondrial 
release of Cyt-c, while the pro-apoptotic proteins act by promoting it, and the fate of 
the cell is determined by the tilt in their ratio towards one or the other (Czabotar, 
Lessene, Strasser, & Adams, 2014; Youle & Strasser, 2008). Importance of Bcl-2 
family proteins in apoptosis regulation is further justified by the number of anticancer 
lead molecules that target the Bcl-2 family of proteins which are currently under 
clinical trial (Wong, 2011). 
Inhibitors of apoptosis proteins: These are a group of functionally and structurally 
related proteins that serve as endogenous inhibitors of apoptosis by inhibiting the 
activity of both initiator and effector caspases. In addition, IAPs are also implicated 
in cell survival and proliferation (Fulda & Vucic, 2012; Gyrd-Hansen & Meier, 2010). 
In humans, eight IAP members have been identified, of which cIAP-1, cIAP-2, XIAP, 
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and survivin are well known. The expression and/or function of IAP proteins are 
significantly altered in a number of human cancers, and are associated with tumor 
progression, poor prognosis, and resistance to chemotherapy (Fulda & Vucic, 2012; 
Gyrd-Hansen & Meier, 2010). For example, increased activity of IAPs are implicated 
in cancers of lung (Hofmann, Simm, Hammer, Silber, & Bartling, 2002), cervix 
(Imoto et al., 2002), kidney (Ramp et al., 2004), prostate (Krajewska et al., 2003), 
breast (Y. Zhang et al., 2011), colon (Xiang, Wen, Wang, Chen, & Liu, 2009), thyroid 
(L. Q. Gu et al., 2009), pancreas (Vogler et al., 2009), and leukemia (Fulda & Vucic, 
2012; Hundsdoerfer, Dietrich, Schmelz, Eckert, & Henze, 2010). IAPs directly inhibit 
apoptosis and promote resistance to chemotherapy by several mechanisms: (1) 
XIAP directly antagonizes the apoptotic functions of caspase-3, -7, and -9, (2) XIAP, 
cIAP-1 and cIAP-2 induce ubiquitination of caspase-3 and -7, leading to their 
degradation and non-degradative inactivation, (3) cIAP-1, cIAP-2 and XIAP induce 
nuclear factor-kappa B (NFκB) activation, thereby, promoting tumor cell survival and 
chemoresistance, (4) survivin complexes with XIAP and protects it from 
ubiquitination and degradation, and finally (5) survivin inhibits the release of 
Smac/DIABLO from mitochondria (Ceballos-Cancino, Espinosa, Maldonado, & 
Melendez-Zajgla, 2007; Dohi, Xia, & Altieri, 2007; Gyrd-Hansen & Meier, 2010). 
Given their prime importance in tumor progression and chemoresistance, several 
IAP-based anticancer therapeutic strategies have been exploited via targeting the 
inhibition of IAP expression and function, amongst them, Smac-derived peptides, 
Smac-mimetics, IAP antagonists and antisense oligonucleotides have gained most 
of the attention (Fulda & Vucic, 2012). Owing to their important role in cancer 
survival, a large number of potential IAP-based anticancer agents are currently 
undergoing clinical trial (Owens, Gilmore, Streuli, & Foster, 2013). 
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2.3 Sanguinarine 
2.3.1 Overview of sanguinarine 
Sanguinarine (13-methyl-[1,3]benzodioxolo[5,6-c]- 1,3-dioxolo[4,5-
i]phenanthridinium) (C20H14NO4) (Fig. 2.2) is a quaternary benzophenanthridine 
alkaloid encountered in many plant species of Papaveraceae family. 
 
 
 
 
 
Figure 2.2. Molecular structure of sanguinarine 
 
 Sanguinarine is mainly extracted from the roots of bloodroot 
plant (Sanguinaria canadensis) (Deroussent, Ré, Hoellinger, & Cresteil, 2010), 
seeds of Mexican prickly poppy (Argemone Mexicana) (Deroussent et al., 
2010), roots and aerial parts of greater celandine (Chelidonium majus) (Colombo & 
Bosisio, 1996; Meng et al., 2009), and fruits and leaves of plume poppy (Macleaya 
cordata) (E. J. Lee, Hagel, & Facchini, 2013; Yao et al., 2010) (Fig. 2.3). It is also 
found in eastern horned poppies (Dicranostigma lactucoides), opium poppy 
(Papaver somniferum), and Kelway's Coral Plume (Macleaya microcarpa). 
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Figure 2.3. Biological sources of sanguinarine. (A) Sanguinaria Canadensis, (B) 
Macleaya cordata, (C) Chelidonium majus, and (D) Argemone Mexicana. 
 
Sanguinarine and extracts of SNG-containing plants have long been used in 
tooth pastes and other oral hygiene products due to its anti-plaque and anti-
inflammatory properties (Hannah, Johnson, & Kuftinec, 1989; Kuftinec, Mueller-
Joseph, & Kopczyk, 1990). Furthermore, Sanguiritrin (a mixture of SNG and a 
structurally similar alkaloid, chelerythrine) has been used as a veterinary preparation 
for the treatment of mastoiditis in cows (Postova et al., 2006). It is also used in 
animal husbandry as an additive to animal feeds (Sangrovit) (Zdarilova et al., 2008). 
A wide range of pharmacological activities have been documented for SNG, 
including antihypertensive (Mackraj, Govender, & Gathiram, 2008; R. Singh, 
Mackraj, Naidoo, & Gathiram, 2006), antimicrobial (Hamoud, Reichling, & Wink, 
2014; Obiang-Obounou et al., 2011), and anti-inflammatory (Lenfeld et al., 1981; 
Niu, Fan, Li, Xing, & Huang, 2012) activities. SNG has received significant attention 
over the past few decades due to its anticancer properties (Choi et al., 2008; Dong 
et al., 2013; S. Gu et al., 2015; Hammerová et al., 2011; Jang et al., 2009; Kalogris 
et al., 2014; S. Kim et al., 2008; Rosen et al., 2015). 
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2.3.2 Pharmacokinetics and toxicological parameters of sanguinarine 
Only limited information is available on the pharmacokinetics and 
toxicological parameters of SNG. Gastrointestinal absorption of SNG is poor, which 
may be due to its quaternary nitrogen atom (Becci, Schwartz, Barnes, & Southard, 
1987; Hong, Moon, & Shim, 2006). In an in vivo experiment conducted in rats, it was 
reported that only 2% of sanguiritrin was absorbed from the gastric tract following its 
daily oral administration (10 mg/kg animal body weight) for 109 days. The remaining 
alkaloid was unabsorbed and excreted in the feces (Postova et al., 2006). Following 
absorption, SNG was found to be distributed in plasma, liver, and kidney of pigs and 
rats (Kosina et al., 2004; Postova et al., 2006). Psotova et al. and Vecera et al. 
identified that dihydrosanguinarine (DHSNG), a less toxic benzophenanthridine, as 
the principal metabolite of SNG (Psotová et al., 2006; Vecera et al., 2007). 
Kosina et al. also conducted an in vivo safety assessment of sanguiritrin (5 
mg/kg body weight) in pigs following its oral administration for 90 days. In this study, 
there were no signs of toxicity and impairment in the health status of the animals. 
Histological examination of gastrointestinal tract, cardiac myocardium, renal cortex, 
and hepatic parenchyma did not reveal any pathological changes (Kosina et al., 
2004). Analogous results were also observed by Psotova et al., after oral 
administration of a higher dose of sanguiritrin (10 mg/kg body weight) in rats for 109 
days (Postova et al., 2006). Studies conducted using Sangrovit also demonstrated 
the safety of SNG. Indeed, administration of Sangrovit for 90 days at doses higher 
than the daily recommended dosage were well tolerated in rats and they were free 
from systemic toxicity (Stiborova et al., 2008; Zdarilova et al., 2008). In addition, 
studies with oral DHSNG (58 mg/kg body weight) for 90 days also showed no 
evidence of systemic toxicity (Vrublova et al., 2008). Contrary to the above, toxic 
effect of SNG have been reported in a few studies. Das et al. demonstrated that 
intraperitoneal administration of SNG (10 and 15 mg/kg body weight) induced a 
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significant number of chromosome aberrations and sister chromatid exchanges in 
bone marrow cells (Das, Mukherjee, & Chakrabarti, 2004). In addition, single 
intraperitoneal administration of SNG (10 mg/kg body weight) in rats substantially 
increased the activity of serum glutamic-pyruvic transaminase (SGPT) and serum 
glutamic-oxaloacetic transaminase (SGOT), demonstrating its potential 
hepatotoxicity (Dalvi, 1985). These studies used SNG at a concentration of 10 mg or 
higher/kg body weight. Kosina et al. and Psotova et al. attributed these toxicity to the 
high dose administration via intraperitoneal route (Kosina et al., 2004; Mackraj et al., 
2008; Postova et al., 2006). 
2.3.3 Anticancer effects of sanguinarine 
Although SNG was isolated in the late 1940s, extensive studies on the 
mechanism underlying SNG-mediated tumor suppression have only been carried 
out during the past two decades (Kalogris et al., 2014; Sarkar, 1948). During this 
time, numerous in vivo and in vitro studies have been published signifying the 
anticancer properties of SNG.  Some of the important anticancer functions of SNG 
are induction of apoptosis (S. Gu et al., 2015; Rosen et al., 2015), autophagy 
(Pallichankandy, Rahman, Thayyullathil, & Galadari, 2015), oncosis (Ding et al., 
2002; Weerasinghe, Hallock, & Liepins, 2001), cell cycle arrest (Adhami et al., 2004; 
Reagan-Shaw, Breur, & Ahmad, 2006), and chemosensitization (W. Y. Choi et al., 
2009; Gatti et al., 2014; S. Kim et al., 2008). SNG has also shown to inhibit invasion 
and metastasis (Kalogris et al., 2014; S. Y. Park, Jin, Kim, Lee, & Park, 2014; Sun et 
al., 2012). These effects of SNG are illustrated in Fig. 2.4. 
20 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Anticancer effects of sanguinarine and its main targets. Various tumor 
suppressive functions of SNG such as induction of apoptosis, autophagy, and 
chemosensitization, as well as, inhibition of angiogenesis, invasion and metastasis 
are illustrated with major molecular targets that are involved in each process. 
 
Most of the anticancer activities of SNG have been attributed to its ability to 
induce apoptosis. SNG has been shown to inhibit cancer cell growth through 
induction of apoptosis in a number of different cancers such as skin (Hammerová et 
al., 2011; Rosen et al., 2015), lung (S. Gu et al., 2015; Jang et al., 2009), breast 
(Choi et al., 2008; Dong et al., 2013; Kalogris et al., 2014; S. Kim et al., 2008), 
bladder (Han, Park, et al., 2013; J. S. Lee, Jung, Jeong, Yoon, & Kim, 2012), colon 
(Han, Kim, Yoo, & Choi, 2013; J. S. Lee et al., 2012), cervix (Xu et al., 2012), 
prostate (Adhami et al., 2004; Debiton, Madelmont, Legault, & Barthomeuf, 2003; 
Sun et al., 2010), bone (H. Park et al., 2010), blood (Han, Yoo, & Choi, 2008; 
Hussain et al., 2007), brain (Cecen, Altun, Ercetin, Aktas, & Olgun, 2014; Han et al., 
2007), and pancreas (Ahsan, Reagan-Shaw, Breur, & Ahmad, 2007). 
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2.3.4 Molecular targets of sanguinarine 
The anticancer properties of SNG are manifested through its action on 
various targets. The most established targets are summarized below. 
Caspases: SNG has shown to activate caspase-3, -8, and -9 in T24, EJ, and 5637 
human bladder cancer cells (Han, Park, et al., 2013), HCT-116 colorectal cancer 
cells (Han, Kim, et al., 2013), SK-MEL-2 melanoma cells (Burgeiro, Bento, Gajate, 
Oliveira, & Mollinedo, 2013), HaCaT immortalized human keratinocytes (Adhami, 
Aziz, Mukhtar, & Ahmad, 2003), and HL-60 and CEM leukemia cells (Jang et al., 
2009; Kaminskyy, Kulachkovskyy, & Stoika, 2008). SNG can also impart anticancer 
effects via activation of caspase-7 in BxPC-3 and MIA PaCa-2 pancreatic cancer 
cell lines (C. K. Singh et al., 2015), HaCaT immortalized human keratinocytes 
(Adhami et al., 2003), and SK-MEL-2 melanoma cells (Burgeiro et al., 2013). 
Caspase-4 and -10 have also been shown to be activated in SK-MEL-2 melanoma 
cells (Burgeiro et al., 2013). 
B-cell lymphoma-2 proteins: SNG has been shown to up-regulate pro-apoptotic 
Bcl-2 members such as Bcl-2-associated X protein (Bax) and BH3 interacting-
domain death agonist (Bid), leading to apoptosis induction in AsPC-1 and BxPC-3 
pancreatic cancer cells (Ahsan et al., 2007), primary effusion lymphoma cells 
(Hussain et al., 2007), and DU145 prostate cancer cells (Malíková, Zdarilová, 
Hlobilková, & Ulrichová, 2006). Role of SNG in the regulation of anti-apoptotic Bcl-2 
members such as Bcl-2, B-cell lymphoma-extra-large (Bcl-xL), and myeloid cell 
leukemia 1 (Mcl-1) have also been reported. For example, SNG has been shown to 
decrease the expression of Bcl-2 in HCT-116 colorectal cancer cells (Han, Kim, et 
al., 2013), AsPC-1 and BxPC-3 pancreatic cancer cells (Ahsan et al., 2007), MDA-
231 breast cancer cells (S. Kim et al., 2008), HeLa and SiHa human cervical cancer 
cells (Xu et al., 2012), and HT-29 human colon cancer cells (J. S. Lee et al., 2012). 
Furthermore, SNG has also been shown to down-regulate the expression of Bcl-xL 
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in a variety of cancer cells (Ahsan et al., 2007; Hammerová et al., 2011; Reagan-
Shaw et al., 2006). Another important anti-apoptotic Bcl-2 member down-regulated 
by SNG is Mcl-1. Hammerova et al. observed that SNG down-regulates the 
expression of Mcl-1 in A-375 and SK-MEL-2 melanoma cells (Hammerová et al., 
2011).  
Inhibitors of apoptosis protein: Numerous studies have reported the role of SNG 
in the down-regulation of IAP family of proteins. For instance, SNG-induced 
inactivation of XIAP has been reported in T24, EJ, and 5637 bladder cancer cells 
(Han, Park, et al., 2013), MDA-MB-231 breast cancer cells (S. Kim et al., 2008), 
HCT-116 colorectal cancer cells (Han, Kim, et al., 2013), A-375 and SK-MEL-2 
melanoma cells (Hammerová et al., 2011), and in different primary effusion 
lymphoma cells (Hussain et al., 2007). Sue et al. demonstrated that SNG induces 
survivin degradation through the ubiquitin proteasome-dependent pathway in DU145 
prostate cancer cells (Sun et al., 2010). In addition to XIAP and survivin, SNG has 
been shown to down-regulate cIAP-2 in MDA-MB-231 breast cancer cells (S. Kim et 
al., 2008), cIAP-1 in HCT-116 colorectal cancer cells (Han, Kim, et al., 2013), and 
both cIAP-1 and cIAP-2 in different primary effusion lymphoma cells (Hussain et al., 
2007). 
Reactive oxygen species: Numerous studies suggest that ROS generation by 
SNG initiates many of its antiproliferative and tumor suppressive functions. For 
instance, SNG has been shown to induce ROS-dependent activation of Early growth 
response gene-1 (Erg-1) and subsequent induction of apoptosis in human bladder 
(T24, EJ, and 5637) and colorectal cancer (HCT-116) cell lines (Han, Kim, et al., 
2013; Han, Park, et al., 2013). Treatment with ROS scavenger significantly 
abrogates the Erg-1 activation, and subsequent apoptosis induction, demonstrating 
that ROS-mediated Erg-1 activation is a vital step in apoptosis. ROS production 
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accompanying the anticancer effects of SNG has also been demonstrated in various 
cancer cell lines (Dong et al., 2013; Hussain et al., 2007; Kaminskyy, 
Kulachkovskyy, et al., 2008; S. Kim et al., 2008; Matkar, Wrischnik, & Hellmann-
Blumberg, 2008a, 2008b). 
Other targets: In addition to the above mentioned pathways, SNG has been shown 
to modulate several other important pathways. Some of the other important SNG 
targets include: (1) inhibition of potent pro-angiogenic vascular endothelial growth 
factor (VEGF) (Basini, Santini, Bussolati, & Grasselli, 2007; Eun & Koh, 2004), (2) 
down-regulation of signal transducer and activator of transcription 3 (Stat3)-
mediated pro-tumorigenic targets (Kalogris et al., 2014; Sun et al., 2012), (3) 
overcoming ATP binding cassette (ABC) transporters-mediated tumor resistance 
(Ding et al., 2002; Eid, El-Readi, Eldin, Fatani, & Wink, 2013; Gatti et al., 2014; 
Weerasinghe, Hallock, Tang, Trump, & Liepins, 2006), (4) induction of extracellular 
signal-regulated kinase 1/2 (ERK1/2) phosphorylation (activation), leading to the 
activation of autophagic cell death in U87MG and U118MG malignant glioma cells 
(Pallichankandy et al., 2015), and (5) down-regulation of mRNA levels of matrix 
metalloproteases (MMP-2 and -9), leading to decrease in their activities (Y. H. Choi 
et al., 2009). 
2.4 Reactive oxygen species 
2.4.1 Introduction to reactive oxygen species 
Reactive oxygen species are heterogeneous group of highly reactive ions 
and molecules derived from molecular oxygen (O2) (Schieber & Chandel, 2014). 
Some of the most important ROS with physiological significance are free radicals 
such as hydroxyl radical (•OH), superoxide anion (O2•−), as well as non-radical 
molecules like hydrogen peroxide (H2O2) (Auten & Davis, 2009; Schieber & 
Chandel, 2014). When introduced for the first time, ROS were thought to be very 
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toxic and only associated with various pathological conditions (Brieger, Schiavone, 
Miller, & Krause, 2012). Since then, tremendous amount of published research has 
linked ROS to various physiological process as well (D'Autréaux & Toledano, 2007; 
Weidinger & Kozlov, 2015). In this context, the biological reality of ROS is more 
complex and paradoxical (D'Autréaux & Toledano, 2007; Fruehauf & Meyskens, 
2007; Halliwell, 2013). ROS is involved in numerous biological processes that are 
important for the integrity and fitness of living organisms; yet, ROS is also implicated 
in various disease states such as cancer, diabetes mellitus, atherosclerosis, and 
cardiovascular diseases, to name few (Birben, Sahiner, Sackesen, Erzurum, & 
Kalayci, 2012). 
2.4.2 Reactive oxygen species generation 
Reactive oxygen species, as byproducts of oxygen metabolism, are 
constantly produced and removed via a variety of complex biosynthetic and 
degradative pathways. O2•− is generally considered as the primary ROS which can 
be rapidly inactivated by superoxide dismutase (SOD), yielding H2O2. In the 
presence of Fe2+ or Cu2+ ions, H2O2 can be further converted to •OH in a process 
called the Fenton reaction (Fig. 2.5) (Glasauer & Chandel, 2014; Schieber & 
Chandel, 2014). 
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Figure 2.5. Reactive oxygen species formation and clearance. Major sources of 
ROS formation and antioxidant system involved in ROS conversion and clearance 
are illustrated. 
 
Different types of ROS have different diffusion capabilities and reactivity 
towards their targets. For instance, •OH is extremely reactive and does not diffuse 
outside their site of formation, while O2•− is highly active and has limited diffusion 
capacity, especially through certain channels. In contrast, H2O2 readily diffuses 
through membranes, making it an ideal candidate for intracellular signaling 
(Wojtovich & Foster, 2014). ROS generation can be triggered by several exogenous 
and endogenous factors. Mitochondria-catalyzed electron transport chain (ETC) is 
the major endogenous source of ROS in most mammalian tissues (Sena & Chandel, 
2012). In ETC, mainly at complex I and III, O2•− is formed in the mitochondrial matrix 
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by the single electron reduction of O2 (Saybaşili, Yüksel, Haklar, & Yalçin, 2001; 
Staniek, Gille, Kozlov, & Nohl, 2002). Simultaneously, complex III can also release 
O2•− into the mitochondrial intermembrane space (Muller, Liu, & Van Remmen, 
2004). Some of the other important endogenous sources of ROS are enzymes such 
as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) (Vignais, 
2002), xanthene oxidase (Hodges, Young, Paul, & Ingold, 2000), and lipoxygenase 
(L. Zuo, Christofi, Wright, Bao, & Clanton, 2004). In addition, ROS generation can 
be facilitated by a multitude of exogenous factors such as radiation, drugs and 
chemicals, heavy metals, etc. (Cadenas, 1989). 
2.4.3 Conversion and clearance of reactive oxygen species 
The balance between production and scavenging of ROS is of critical 
importance as ROS have been linked with number of biological processes and 
pathophysiological conditions. Cellular redox balance is typically maintained by a 
powerful battery of antioxidant system that is present in different subcellular 
compartments (Hanschmann, Godoy, Berndt, Hudemann, & Lillig, 2013; Perkins, 
Nelson, Parsonage, Poole, & Karplus, 2015). These antioxidant species can be 
divided into (1) enzymatic: SOD, catalase, peroxiredoxin (Prx; also known as 
thioredoxin peroxidase) system, glutathione peroxidase (GPx) system, etc. and (2) 
non-enzymatic: L-ascorbic acid, α-lipoic acid, α-tocopherol, etc. 
As mentioned earlier, SOD catalyzes the conversion of O2•− into H2O2, which 
can be further reduced to water by Prx system, GPx system, and catalase (Fig. 2.5). 
The Prx system consists of two electron donors and two types of antioxidant 
enzymes: Prx itself, thioredoxin reductase (TrxR), thioredoxin (TRX), and NADPH. 
During the metabolism of H2O2, Prx gets oxidized and inactivated. TRX acts as an 
immediate electron donor and reduces Prx back to active form. Consequently, TRX 
is reduced by TrxR which receives its electrons from NADPH (Fig. 2.5). In the GPx 
system, GPx catalyses the reduction of H2O2 leading to the oxidation of glutathione 
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(GSH), which can be reduced back by glutathione reductase (GR), using NADPH 
(Fig. 2.5) (Brigelius-Flohé & Maiorino, 2013). 
2.4.4 Apoptotic functions of reactive oxygen species 
Cancer cells exhibit greater ROS level than normal cells. Nevertheless, 
these ROS levels are counteracted by increased activity of antioxidant enzymes in 
cancer cells. This common effect suggests that the therapeutic strategies, which 
either increase ROS generation or decrease antioxidant defense, may push cancer 
cells beyond the breaking point, leading to the activation of different cell death 
pathways, thus limiting the cancer progression. Accordingly, large variety of 
anticancer agents effectively kill cancer cells and overcome drug resistance via 
modulating ROS generation and antioxidant defense.  
Induction of apoptosis is one of the key tumor suppressive functions of ROS. 
Cellular FLICE-inhibitory protein (c-FLIP) competes with the procaspase for adaptor 
protein binding site, leading to the inhibition of DISC formation, and subsequent 
activation of apoptosis (Safa, 2012). ROS have been shown to negatively regulate 
c-FLIP post-transcriptionally, leading to the facilitation of extrinsic pathway of 
apoptosis (L. Wang et al., 2008). Two different mechanisms have been proposed for 
ROS-dependent down-regulation of c-FLIP: (1) Through negatively regulating nitric 
oxide that prevents S-nitrosation and ubiquitin-proteasomal degradation of c-FLIP 
(Chanvorachote et al., 2005; L. Wang et al., 2008) and (2) ubiquitination of c-FLIP 
(phospho-Thr166) at Lys167, leading to its subsequent degradation by proteasomes 
(Wilkie-Grantham, Matsuzawa, & Reed, 2013).  
Being the major source of ROS generation, most of the apoptosis-inducing 
actions of ROS is undoubtedly in the mitochondria. During the PTP formation, a 
number of proteins associate to form a non-selective pore at the mitochondrial 
membrane. The three major components of PTP are voltage-dependent anion-
selective channel (VDAC; also known as porin), adenine nucleotide translocase 
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(ANT), and cyclophilin D (Marchi et al., 2012). Madesh and Hajnoczky demonstrated 
that O2•−, but not H2O2, triggers rapid and massive Cyt-c release, leading to the 
induction of apoptosis via VDAC-dependent permeabilization of mitochondria 
(Madesh & Hajnóczky, 2001).  Additionally, McStay et al. demonstrated that 
oxidation of ANT at Cys160 and Cys257 promotes the opening of the PTP (McStay, 
Clarke, & Halestrap, 2002). In mitochondria Cyt-c exists as a complex with 
cardiolipin, therefore, the complex must be breached in order to facilitate its release. 
In the presence of H2O2, cardiolipin gets oxidized, reducing its affinity for Cyt-c, 
leading to its release into the cytosol (Bayir & Kagan, 2008; Kagan et al., 2005). As 
mentioned earlier, following the release from mitochondria, Cyt-c must interact with 
Apaf-1 and procaspase-9, to form apoptosome. Zuo et al. demonstrated that 
oxidative modification of Cys403 of procaspase-9 can mediate its interaction with 
Apaf-1 via disulfide bond formation, and can thus promote its auto-cleavage and 
activation (L. Zhang et al., 2015; Y. Zuo et al., 2009). An alternative mechanism for 
oxidation-dependent caspase-9 activation has also been proposed. Katoh et al. 
demonstrated that H2O2 induces disulfide bridge-mediated dimer formation of 
caspase-9 in the mitochondria, leading to its auto-proteolytic cleavage and 
subsequent activation in Apaf-1-independent manner (Muller et al., 2004; L. Zhang 
et al., 2015).  
The process of apoptosis can be positively or negatively regulated by a large 
variety of tumor suppressive and proliferative proteins and lipids. Many of the 
current anticancer therapies have been shown to exert their cytotoxicity via ROS-
dependent regulation of these proteins and lipids. For instance, ROS have been 
shown to induce apoptosis signal-regulating kinase 1 (ASK1) dimer formation, 
leading to its activation (Gotoh & Cooper, 1998). Activation of ASK1 induces 
phosphorylation and activation of MAPKs such as c-Jun N-terminal kinases (JNK) 
and p38, leading to the induction of the intrinsic pathway of apoptosis (Hatai et al., 
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2000). Another key mediator of the biological effects of ROS is the tumor suppressor 
lipid ceramide. A strong interplay between ceramide generation and oxidative stress 
has been demonstrated. ROS generation were reported to generate ceramide in 
lipid rafts; specialized micro-domains of plasma membrane that contain high 
concentrations of lipids (Galadari et al., 2013). For example, ROS-dependent 
accumulation of ceramide in raft micro-domains was observed following ultraviolet 
(UV)-irradiation (Charruyer et al., 2005) and TNF-related apoptosis inducing ligand 
(TRAIL) treatment (Dumitru & Gulbins, 2006). Similar results were also observed in 
radiosensitive human head and neck squamous carcinoma cell line (SCC61) 
following gamma-irradiation (Bionda et al., 2007). 
2.5 Ceramide 
2.5.1 Introduction to sphingolipids 
Sphingolipids comprise a complex family of membrane lipids which are 
ubiquitously expressed in eukaryotic cells. Currently, sphingolipids are also 
implicated in mediating a wide variety of intracellular functions (Galadari et al., 2015; 
Hannun & Obeid, 2008). Ceramide is the most crucial sphingolipid molecule which 
mediates a variety of antiproliferative cellular responses. Diverse array of stressors 
such as genotoxic damage, inflammatory mediators, heat shock, oxidative stress, 
and anticancer drugs can induce ceramide generation, which in turn orchestrates a 
myriad of tumor suppressive signaling pathways such as apoptosis, autophagy, 
senescence, and necroptosis (Albi et al., 2006; Galadari et al., 2015; Hannun & 
Obeid, 2008; Kimura, Markowski, Edsall, Spiegel, & Gelmann, 2003; MacKichan & 
DeFranco, 1999; Pfeilschifter & Huwiler, 1998; Yabu, Imamura, Yamashita, & 
Okazaki, 2008). 
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2.5.2 Ceramide biosynthetic pathway 
The biosynthetic pathway of sphingolipids consists of a complex network of 
synthetic and degradative reactions. Some of the major pathways of intracellular 
ceramide accumulation are (1) de novo pathway of ceramide synthesis, (2) 
sphingomyelinase (SMase)-mediated hydrolysis of sphingomyelin, and (3) inhibition 
of ceramidase (CDase)- or glucosylceramide synthase (GCS)-mediated conversion 
of ceramide into sphingosine and glucosylceramide, respectively, and (4) catabolism 
of complex glycosphingolipids (GSL) by different glycosidases (Galadari et al., 2013; 
Galadari et al., 2015). Ceramide biosynthetic pathway and inhibitors of various 
ceramide biosynthetic enzymes are depicted in Fig. 2.6. 
 
Figure 2.6. Schematic representation of ceramide biosynthetic pathway that 
illustrates enzymes that catalyze each step and their inhibitors. Adapted from: 
Galadari S, Rahman A, Pallichankandy S, Thayyullathil F. Tumor suppressive 
functions of ceramide: evidence and mechanisms. Apoptosis. 2015; 20(5):689-711. 
 
The de novo ceramide biosynthesis begins in the ER with condensation of 
palmitoyl-CoA and the amino acid serine, catalyzed by the action of an enzyme 
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called serine palmitoyl transferase (SPT), which proceeds through a series of 
reducing, acylating, and oxidizing reactions until ceramide is formed (Fig. 2.6) 
(Galadari et al., 2013; Galadari et al., 2015). Ceramide may be hydrolyzed by 
CDase to generate sphingosine, which may be further phosphorylated to 
sphingosine-1-phosphate (S1P) by sphingosine kinase. Ceramide synthase and 
S1P phosphatase can reverse the formation of sphingosine from ceramide and S1P 
from sphingosine, respectively (Fig. 2.6) (Galadari et al., 2013; Galadari et al., 
2015). Once ceramide is formed in the ER, ceramide transfer protein transport 
ceramide to the Golgi, where it can be converted into sphingomyelin and 
glucosylceramide by the action of sphingomyelin synthase and GCS, respectively. 
Glucosylceramide can be further converted to the complex GSL by different sialyl 
transferases (Galadari et al., 2013; Galadari et al., 2015). 
2.5.3 Role of ceramide in apoptosis 
One of the key tumor suppressive functions of ceramide is its ability to 
induce apoptotic cell death in variety of tumor models. Ceramide exercises its 
apoptosis-inducing activity via directly or indirectly modulating a diverse range of 
molecular targets as depicted in Fig. 2.7. 
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Figure 2.7. Pathways of ceramide-driven apoptotic response. Major molecular 
targets that are involved in the ceramide-induced extrinsic, intrinsic and ER-stress 
mediated apoptotic responses are shown. Adapted from: Galadari S, Rahman 
A, Pallichankandy S, Thayyullathil F. Tumor suppressive functions of ceramide: 
evidence and mechanisms. Apoptosis. 2015; 20(5):689-711. 
 
Some of the important pro-apoptotic targets of ceramide are (1) ceramide-
activated protein phosphatases (CAPP): protein phosphatase-2A (PP2A), protein 
phosphatase-1 (PP1), and protein phosphatase-2C (PP2C), (2) protein kinase C 
(PKC), (3) MAPKs: JNK and p38, (4) mitochondrial pro-apoptotic proteins: Cyt-c, 
AIF, EndoG, and Smac/DIABLO, (5) caspases, (6) cathepsin D, (7) p53, (8) Bcl-2 
family proteins, and (9) ER stress proteins.  
A significant body of previous reports have shown the role of ceramide in the 
activation of extrinsic and intrinsic pathway of apoptosis. For instance, activation of 
TRAIL receptors was shown to induce ROS-dependent acid sphingomyelinase 
(aSMase) activation, leading to subsequent ceramide generation and formation of 
ceramide-enriched membrane domains. These domains serve as signaling 
platforms, where clustering of various death receptors mediates proximity-induced 
caspase activation and subsequent induction of extrinsic pathway of apoptosis 
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(Dumitru & Gulbins, 2006; Galadari et al., 2015). In addition, ceramide has also 
been shown to down-regulate caspase-8 inhibitor, c-FLIP protein (Asakuma, 
Sumitomo, Asano, & Hayakawa, 2003; Galadari et al., 2015; Yoon et al., 2002). As 
mentioned earlier, ceramide has been implicated in the induction of the intrinsic 
pathway of apoptosis. Various mechanism have been proposed for this: (1) 
activation of Bax leading to the release of Cyt-c (Birbes et al., 2005; Galadari et al., 
2015; Kashkar, Wiegmann, Yazdanpanah, Haubert, & Krönke, 2005), (2) directly 
forming channels in the mitochondrial membrane (Galadari et al., 2013; Siskind, 
Kolesnick, & Colombini, 2006), (3) inhibition of Akt activation and thereby preventing 
the Akt-induced inactivation of pro-apoptotic Bcl-2 proteins (Galadari et al., 2015; 
Navarro, Valverde, Rohn, Benito, & Lorenzo, 2000), and (4) translocation of PKCδ 
to the mitochondria, which in turn, leads to the release of Cyt-c and caspase-9 
activation (Galadari et al., 2015; Sumitomo et al., 2002). 
2.5.4 Ceramide activated protein phosphatases 
Ceramide has been shown to mediate many of its biological effects via 
activation of serine/threonine protein phosphatases (PP1 and PP2A) collectively 
referred to as CAPPs. Some of the important substrates of CAPPs include Akt, Bcl-
2, c-Jun, retinoblastoma (Rb) protein, PKCα, DAPK, and ERM (ezrin, radixin, and 
moesin) proteins (Galadari et al., 2015). Numerous studies have shown that CAPPs 
dephosphorylate Akt and oppose its anti-apoptotic actions (Galadari et al., 2015; 
Salinas, López-Valdaliso, Martín, Alvarez, & Cuadrado, 2000; Schubert, Scheid, & 
Duronio, 2000; Zhu et al., 2011). For instance, Schubert et al. have demonstrated 
that treatment of TF-1 human erythroleukemia and PC-12 rat pheochromocytoma 
cells with exogenous ceramide mediates CAPP-dependent dephosphorylation of Akt 
at Ser473 (Schubert et al., 2000). 
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2.6 Akt 
2.6.1 Overview of Akt 
Akt is a serine-threonine protein kinase that plays a key role in multiple 
tumorigenic cellular processes such as cell proliferation, cell cycle progression, 
inhibition of apoptosis, and induction of cell motility, angiogenesis and metastasis 
(Brazil, Park, & Hemmings, 2002; Qiao, Sheng, & Pardee, 2008). The three highly 
homologous isoforms of mammalian Akt which been identified so far are Akt1 
(PKBα), Akt2 (PKBβ), and Akt3 (PKBγ) (Scheid & Woodgett, 2003). These isoforms 
share similar structural organization, but appear to have variability in cellular 
distribution and carry distinct biological processes (Laine, Künstle, Obata, & 
Noguchi, 2002). Akt1 is ubiquitously expressed in a wide variety of tissues and is 
implicated in cell growth and survival, while Akt2 is highly expressed in adipose 
tissues, liver, and skeletal muscles, and is implicated in glucose homeostasis. 
Though virtually seen in all tissues, the expression of Akt3 is more predominant in 
testes and brain (Hers, Vincent, & Tavaré, 2011). 
2.6.2 Akt in cancer 
Over past few decades, significant advances have been made in 
understanding the biological processes that are regulated by Akt. Akt has emerged 
as a central player in cellular survival and proliferation. Considering its proliferative 
functions, Akt has one of the highest number of mutation associated with cancer 
(Fresno Vara et al., 2004). For instance, somatic missense activating mutation of 
Akt1 (E17K) was found in breast, colorectal, and ovarian cancers (Carpten et al., 
2007). Moreover, gene amplifications in different Akt isoforms have been 
demonstrated in pancreatic and head and neck cancers (Engelman, Luo, & Cantley, 
2006; Yuan & Cantley, 2008). In addition to tumorigenesis, constitutive activation of 
Akt is also associated with poor prognosis and resistance to chemotherapy 
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(Morishita et al., 2012; Yoshioka et al., 2008). Therefore, therapeutic strategies that 
target Akt may ultimately prove more efficacious for the management of cancer. 
Simultaneously, many such compounds (perifosine, MK2206, GDC-0068, 
GSK2110183, and ARQ 092) are in clinical trial or in the development pipeline 
(Dienstmann, Rodon, Serra, & Tabernero, 2014). 
2.6.3 Regulation of Akt 
The signaling events required for the Akt activation are well characterized. 
Akt is one of the key downstream mediator of the phosphoinositide 3-kinase (PI3K) 
cell growth and survival pathway. The PI3K pathway begins at the plasma 
membrane with the binding of growth factors and cytokines to their respective cell-
surface receptors. This binding results in the recruitment and activation of PI3K 
(Galadari et al., 2013). Once activated, PI3K phosphorylates the membrane lipid 
phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-
triphosphate (PIP3) (Galadari et al., 2013). Akt and phosphoinositide dependent 
protein kinase-1 (PDK1) are recruited to the PIP3 and Akt is activated by PDK-
dependent phosphorylation at Thr308 of catalytic domain (Chong, Li, & Maiese, 
2005; Galadari et al., 2013). However, complete activation of Akt requires 
phosphorylation at Ser473 of regulatory domain (Galadari et al., 2013). The 
mechanism of Ser473 phosphorylation is not completely elucidated as yet. Several 
likely candidates have been proposed, including Akt itself, PDK1, PKC, and 
mammalian target of rapamycin (mTOR) complex 2 (Hassan, Akcakanat, Holder, & 
Meric-Bernstam, 2013; Martelli, Evangelisti, Chiarini, & McCubrey, 2010). Following 
its activation, Akt translocates to the cytosol and various subcellular compartments 
such as the nucleus, ER, and mitochondria where it catalyzes the phosphorylation of 
a number of downstream targets leading to tumorigenesis (Bononi et al., 2011) (Fig. 
2.8). 
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Figure 2.8. Pathways of Akt-driven pro-tumorigenic response. Major molecular 
targets that are involved in the Akt-induced proliferation, cell cycle progression, and 
survival responses are shown. 
 
Following its activation, Akt may be inactivated by its dephosphorylation 
which in turn switches off its varied anti-apoptotic functions. As mentioned earlier, 
CAPPs such as PP1 and PP2A can dephosphorylate Akt and oppose its anti-
apoptotic actions (Galadari et al., 2015; Schubert et al., 2000). Apart from directly 
activating CAPPs, ceramide has been shown to reduce the association between 
inhibitor 2 of PP2A (I2PP2A; also known as SET), resulting in increased PP2A 
activity (Chalfant, Szulc, Roddy, Bielawska, & Hannun, 2004; Mukhopadhyay et al., 
2009). Although, it was hypothesized that CAPPs equally dephosphorylates both the 
Thr308 and Ser473 residues, possibility of differential affinity towards each site has 
not been addressed. 
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2.6.4 Downstream targets of Akt 
Some of the important downstream targets of Akt are listed below (Fig. 2.8): 
Glycogen synthase kinase 3 beta: Akt has been shown to phosphorylate glycogen 
synthase kinase 3 beta (GSK3β) at Ser9, leading to its inactivation, and subsequent 
attenuation of its inhibitory effect on anti-apoptotic Bcl-2 member, Mcl-1 (Chalfant et 
al., 2004). Another important primary target for GSK3β is β-catenin, of which 
phosphorylation by GSK3β at Ser33, Ser37, and Thr41 leads to its degradation by 
the 26S proteasome complex (Takahashi-Yanaga & Sasaguri, 2008). Akt-mediated 
inactivation of GSK3β blocks its ability to phosphorylate and degrade β-catenin, 
leading to its accumulation in the nucleus, where it induces the expression of 
tumorigenic Wnt target proteins such as c-myc, cyclin D1, and VEGF (Takahashi-
Yanaga & Sasaguri, 2008; X. Zhang, Gaspard, & Chung, 2001). In addition, GSK3β 
is also an endogenous inhibitor of eukaryotic initiation factor 2B (elF2B), an 
essential participant in the initiation of protein translation. So, inactivation of GSK3β 
by Akt promotes protein synthesis, a requisite in tumor progression (Galadari et al., 
2013; White-Gilbertson, Kurtz, & Voelkel-Johnson, 2009). 
Forkhead box O transcription factors: Akt has been shown to 
directly phosphorylate forkhead box O (FOXO) transcription factors leading to their 
displacement from target genes, nuclear exclusion and subsequent proteasomal 
degradation (X. Zhang, Tang, Hadden, & Rishi, 2011). Akt-mediated 
phosphorylation of FOXO1 (Thr24, Ser256, and Ser319), FOXO3 (Thr32, Ser253, 
and Ser315), FOXO4 (Thr28, Ser193, and Ser258), and FOXO6 (Thr26 and 
Ser184), may promote their interaction with 14-3-3 chaperone molecules. The 
adapter protein 14-3-3 displaces FOXO from target genes, and escorts their re-
localization from the nucleus to the cytoplasm, thereby inhibiting their transcriptional 
functions (X. Zhang et al., 2011). Through this mechanism, Akt blocks FOXO-
mediated transcription of tumor suppressive genes such as (1) apoptosis inducing 
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death receptor ligands such as FasL and TRAIL, (2) pro-death Bcl-2 family protein 
such as Bcl-2-like protein 11 (Bim), p52 up-regulated modulator of apoptosis 
(PUMA), and Noxa (Latin word for damage), and (3) cyclin-dependent kinase 
inhibitors (CDKI) such as p27Kip1 and p21Cip1 (X. Zhang et al., 2011).  
p53: Akt phosphorylates mouse double minute 2 (MDM2) at Ser166 and Ser186, 
which results in its enhanced nuclear localization, where it negatively regulates p53 
function by potentiating its ubiquitination (Mayo & Donner, 2001; B. P. Zhou, Liao, 
Xia, Zou, et al., 2001). Some of the important transcriptional targets of p53 are: (1) 
pro-apoptotic Bcl-2 members such as PUMA and Noxa, (2) CDKI such as p21Cip1, 
and (3) pro-autophagic genes such as Atg4, Atg7, and Atg10 (Bieging, Mello, & 
Attardi, 2014). 
Cyclin dependent kinase inhibitors: It was shown that Akt could directly 
phosphorylate p27Kip1 at Thr157 and subsequently abolish its nuclear localization 
and CDKI function (Liang et al., 2002; Shin et al., 2002; Viglietto et al., 2002). As 
with p27Kip1, Akt phosphorylates p21Cip1 at Thr145, leading to its cytosolic 
localization and subsequent promotion of cell growth (B. P. Zhou, Liao, Xia, Spohn, 
et al., 2001). 
Mammalian target of rapamycin: Akt directly phosphorylates mTOR at Ser2448, 
leading to mTORC1 activation, which promotes tumorigenesis via activation of p70 
ribosomal S6 kinase (p70S6K) and the inhibition of eukaryotic initiation factor 4E 
binding protein (eIF4EBP) (Galadari et al., 2013). 
B-cell lymphoma-2 proteins: Mitochondrial membrane insertion of Bax is essential 
for the release of pro-apoptotic factors from the mitochondria (Czabotar et al., 2014; 
Youle & Strasser, 2008). Akt phosphorylates Bax at Ser184, thereby inhibiting its 
conformational change necessary for the oligomerization and mitochondrial 
membrane insertion (Gardai et al., 2004; Stiles, 2009; Xin & Deng, 2005). Another 
important Bcl-2 protein which is directly phosphorylated by Akt is Bcl-2-associated 
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death promoter (Bad). Akt directly phosphorylates Bad at Ser136, resulting in its 
dissociation from Bcl-2 or Bcl-xL, thereby regaining the anti-apoptotic functions of 
Bcl-2 and Bcl-xL (Datta et al., 1997; Masters, Yang, Datta, Greenberg, & Fu, 2001). 
Other targets: In addition to the above mentioned functions, Akt has been shown to 
phosphorylate: (1) procaspase-9 at Ser196, leading to a decrease in its proteolytic 
activity (Cardone et al., 1998), (2) I-kappa B Kinase (IKK) at Thr23, thereby inducing 
the transcriptional activation of NFκB, which is widely perceived as an anti-apoptotic 
transcriptional factor (Romashkova & Makarov, 1999), (3) ASK1 at Ser83, thereby 
inhibiting ASK1-mediated JNK activation and subsequent inhibition of apoptosis (A. 
H. Kim, Khursigara, Sun, Franke, & Chao, 2001), and (4) cAMP response element-
binding protein (CREB) transcription factor at Ser133, thereby possibly promoting 
transcription of CREB-regulated survival genes such as Bcl-2 and Mcl-1 (Du & 
Montminy, 1998). 
2.7 Extracellular signal-regulated kinase 1/2 
2.7.1 Introduction to extracellular signal-regulated kinase 1/2 
Mitogen activated protein kinases are highly conserved family of 
serine/threonine protein kinases which regulate wide variety of cellular process such 
as cell growth and differentiation, gene expression, cell motility and invasion, cell 
survival, apoptosis, and autophagy. Three key members of MAPK family are ERK 
(ERK1 and ERK2), JNK (JNK1, JNK2, and JNK3), and p38 (p38α, p38β, p38γ, and 
p38δ) (Lu & Xu, 2006). Human ERK1 and ERK2 share 84% structural identity with 
ERK1 having an additional 17 amino acid residue insertion at its N-terminal 
extension. Most, if not all, the stimulants of the ERK pathway can activate both 
ERK1 and ERK2 independently, and both ERKs possess matching substrate 
specificity (Roskoski, 2012). Considering their overlapping functions, they are 
generally referred to as ERK1/2 (Lloyd, 2006). 
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2.7.2 Regulation of extracellular signal-regulated kinase 1/2 
The canonical ERK1/2 signaling pathway is initiated by the binding of growth 
factors such as epidermal growth factor (EGF) and platelet-derived growth factor 
(PDGF) to their respective tyrosine kinase receptors, leading to their 
autophosphorylation and activation (Bivona & Philips, 2003; Ramos, 2008). 
Receptor activation recruits the adaptor protein growth factor receptor-bound protein 
2 (Grb2) through src homology 2 (SH2) domain, which further recruits and binds to 
guanine nucleotide exchange factor SOS through its src homology 3 (SH3) domain 
(Shaul & Seger, 2007). Following its recruitment, SOS activates membrane-
localized Ras GTPase which subsequently mediates a relay of phosphorylation 
cascade, finally leading to the ERK1/2 activation. Initially, Ras recruits and activates 
Raf kinase (also known as MAPK kinase kinase), which subsequently 
phosphorylates two serine residues on the activation loop of MEK (also known as 
MAPK kinase), leading to its activation (Ramos, 2008; Shaul & Seger, 2007). 
Activated MEK phosphorylates tyrosine and threonine residues on the activation 
loop of ERK1/2 leading to its activation.  
Following its activation, ERK1/2 may be inactivated by its dephosphorylation 
at either or both threonine and tyrosine residues on the activation loop. This action 
may be mediated by (1) dual specificity phosphatases (DUSP) (also known as 
MAPK phosphatase) which dephosphorylates both threonine and tyrosine residues, 
(2) serine/threonine phosphatase such as CAPP (PP2A), and (3) tyrosine 
phosphatase such as phosphotyrosine-specific phosphatase (PTPase) (Roskoski, 
2012). In addition, ERK1/2 activation may also be attenuated by the inhibition of its 
upstream kinases. ERK1/2 can phosphorylate its upstream regulators such as SOS, 
Raf, and MEK, thereby, inhibiting further ERK1/2 activation via a negative feedback 
mechanism (Ramos, 2008). 
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2.7.3 Opposing functions of extracellular signal-regulated kinase 1/2 
Following its activation, ERK1/2 can translocate mainly into the nucleus and 
cytoplasm, but also into other organelles where they can phosphorylate and regulate 
various signaling molecules such as transcription factors, kinases, and cytoskeletal 
proteins (Roberts & Der, 2007). More than 160 substrates with diverse and 
sometimes opposing functions have been identified as ERK1/2 targets (Roberts & 
Der, 2007). ERK1/2 signaling is particularly interesting as it exhibits both tumor 
promoting and tumor suppressive activity (Cagnol & Chambard, 2010). This raises 
the question as to how these varied and opposing functions are regulated by 
ERK1/2. Several mechanisms have been proposed for the specificity determination 
by ERK1/2. These are (1) strength and duration of its phosphorylation, (2) 
interaction with various scaffold proteins and other intracellular signaling 
molecules/pathways, and (3) subcellular localization of ERK1/2 (Shaul & Seger, 
2007). 
2.7.4 Tumor suppressive functions of extracellular signal-regulated kinase 1/2 
Initial reports on the tumor suppressive functions of ERK1/2 signaling 
pathway came in the 1990s where Blagosklonny et al. demonstrated that depletion 
of Raf protects MCF-7 breast cancer cells from taxol-induced apoptosis (Cagnol & 
Chambard, 2010). Since then, numerous articles have been published linking the 
Ras⁄Raf⁄ERK1/2 pathway in the induction of cell death mediated by UV-gamma 
irradiation (Y. J. Lee et al., 2003; Tang et al., 2002), chemotherapeutic agents 
(Martin, Poggi, Chambard, Boulukos, & Pognonec, 2006; X. Wang, Martindale, & 
Holbrook, 2000), phytochemicals (Stefanelli et al., 2002; Yeh et al., 2004), and other 
anticancer therapies (Cagnol & Chambard, 2010). Some of the important pro-
apoptotic mechanism of ERK1/2 include: 
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1. Activation of extrinsic apoptotic pathway: ERK1/2 have been shown to induce 
death ligands (TNF-α and FasL) (Cagnol & Chambard, 2010; Ulisse et al., 
2000), death receptors (FasR, death receptor 4, and death receptor 5) 
(Drosopoulos et al., 2005; Shenoy, Wu, & Pervaiz, 2009; Tanaka et al., 2002; 
Tewari, Sharma, Koul, & Sen, 2008), death inducing adaptor protein (FADD) 
(Tewari et al., 2008), and extrinsic apoptosis initiator caspase (caspase-8) 
(Cagnol, Van Obberghen-Schilling, & Chambard, 2006) in different cancer 
models.  
2. Activation of intrinsic apoptotic pathway: ERK1/2 have also been shown to 
decrease the mitochondrial membrane potential, which could mediate the 
release of Cyt-c from the mitochondria to the cytosol, which may further 
facilitating the intrinsic pathway of apoptosis (G. S. Kim et al., 2003; Nowak, 
Clifton, Godwin, & Bakajsova, 2006; C. L. Zhang et al., 2004; X. Zhang et al., 
2003). In addition, down-regulation of anti-apoptotic Bcl-2 family members (Bcl-2 
and Bcl-xL) (DeHaan, Yazlovitskaya, & Persons, 2001; Li et al., 2007) and up-
regulation of pro-apoptotic Bcl-2 members (Bax and PUMA) (L. Brown & 
Benchimol, 2006; Cagnol & Chambard, 2010; Gomez-Sarosi, Strasberg-Rieber, 
& Rieber, 2009; Panaretakis et al., 2008; Z. Wu, Wu, Tashiro, Onodera, & 
Ikejima, 2005) have also been shown to be facilitated by ERK1/2.  
3. Phosphorylation and stabilization of p53: ERK1/2 bind to and phosphorylate p53 
at Ser15, which subsequently promotes p53 stabilization and accumulation via 
inhibiting its association with MDM2, a negative regulator of p53 (Cagnol & 
Chambard, 2010). 
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Chapter 3: Materials and methods 
 
3.1 Resources and Materials 
3.1.1 Cell lines and culture media 
Human acute T lymphocytic leukemia cells (Jurkat and Molt-4) were 
purchased from ATCC (VA, USA). Tissue culture media such as RPMI 1640 
GlutaMAX medium, phenol red free RPMI, as well as, biochemical such as 
phosphate-buffered saline (PBS), fetal bovine serum (FBS), trypsin-EDTA, and 
penicillin-streptomycin were bought from Gibco BRL (NY, USA). 
3.1.2 Reagents, chemicals, and inhibitors 
Sanguinarine chloride hydrate, methylthiazolyldiphenyl-tetrazolium bromide 
(MTT), dimethyl sulfoxide (DMSO), proteinase K, RNase A, ethidium bromide, L-
GSH reduced, N-Acetyl-L-cysteine (NAC), L-Ascorbic acid, α-Lipoic acid, bovine 
liver catalase, bovine erythrocytes SOD, mitochondria peroxy yellow 1 (MitoPY1), o-
phthaladialdehyde (OPA), myriocin (Myr), fumonisin B1 (FB1), desipramine 
hydrochloride (Desip), uridine 5′-diphosphoglucose disodium salt (UDP-glucose), 
phosphatidic acid (PA), octylphenoxy poly (ethyleneoxy) ethanol (IGEPAL CA-630), 
ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid (EGTA), sodium dodecyl sulfate (SDS), dithiothreitol 
(DTT), phenylmethylsufonyl fluoride (PMSF), Hanks' Balanced Salt solution (HBSS), 
and 1,9-Pyrazoloanthrone (SP600125), caspase-3 colorimetric assay kit and GSH 
assay kit were were purchased from Sigma-Aldrich (MO, USA). Pan-caspase 
inhibitor Z-Val-Ala-Asp-fluoromethylketone (Z-VAD-FMK), DL-threo-1-Phenyl-2-
decanoylamino-3-morpholino-1-propanol (PDMP), C6-ceramide, 1,4-diamino-2,3-
dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126), and 4-(4-Fluorophenyl)-2-(4-
hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole (SB202190) were bought from Enzo 
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(Lausen, Switzerland). 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA), C6-
NBD-ceramide and Amplex red (10-acetyl-3,7-dihydroxyphenoxazine) H2O2 assay 
kit were obtained from Molecular Probes (OR, USA). Calyculin A (CalA) and 
Okadaic Acid (OA) were from Merck Millipore (MA, USA). N-Oleoyl-ethanolamine 
(NOE) was from Matreya (PA, USA), N,N′- Bis[4-(4,5-dihydro-1H-imidazol-2-
yl)phenyl]-3,3′-p-phenylene-bis-acrylamide dihydrochloride (GW4869) was from 
Santa Cruz Biotechnology (TX, USA), H2O2 was from Merck (NY, USA), Sodium 
pyruvate (Sod Pyr) was from GIBCO BRL (NY, USA), and C6-NBD-sphingomyelin 
was from Avanti Polar Lipids (AL, USA). FICT Annexin V apoptosis detection kit was 
purchased from BD pharmingen (NJ, USA), and catalase assay kits were obtained 
from Cayman (MI, USA). 
3.1.3 Antibodies 
Anti-caspase-8, anti-caspase-9, anti-caspase-3, anti-PARP, anti-Akt pS473, 
anti-Akt, anti-PI3K p110β, anti-PI3K p85, anti-PDK1 pS241, anti-PDK1, anti-4EBP1 
pT37/46, anti-4EBP1, anti-mTOR pS2448, anti-mTOR, anti-GSK3β pS9, and anti-
ERK1/2 pT202/Y204 were purchased from Cell Signaling Technology (MA, USA). 
Anti-actin, anti-cIAP-1, anti-cIAP-2, anti-survivin, anti-GSK3β, and anti-ERK1/2, 
were from Santa Cruz Biotechnology (TX, USA). Anti-XIAP was from BD 
Biosciences (NJ, USA). 
3.2 Experimental procedures and methods 
3.2.1 Cell culture and sanguinarine treatment 
Jurkat and Molt-4 cells (ATCC, VA, USA) were grown in RPMI 1640 
GlutaMAX medium supplemented with 10% vol/vol heat-inactivated FBS, 50 IU/mL 
penicillin, and 50 μg/mL streptomycin in an incubator containing humidified 
atmosphere of 95% air and 5% CO2 at 37°C. Sanguinarine was dissolved in DMSO 
at a concentration of 10 mM and was stored in a dark colored bottle at -20°C. The 
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stock was diluted to the required concentration with DMSO as and when needed. 
Prior to SNG treatment, cells were grown to about 80% confluence, and then 
exposed, at the desired concentration, to SNG for the required time period. Cells 
that were grown in a medium containing an equivalent amount of DMSO without 
SNG served as control. 
3.2.2 MTT viability assay 
Cell viability was measured by MTT assay. The assay involves conversion of 
the water soluble yellow colored MTT to an insoluble purple colored formazan. Only 
viable cells having active mitochondrial dehydrogenases are able to catalyze this 
conversion. To perform the assay, leukemic cells (20,000 cells/well) grown in 96-
well flat bottom plates were exposed to the required concentration of SNG. At the 
desired times, 25 μL of MTT (5 mg/mL) in PBS were added to each well. The plates 
were then incubated for a further 4 h at 37°C. After the incubation, the plates were 
centrifuged at 600 g for 5 min and the media were removed from all the wells. The 
remaining formazan crystals were then solubilized in a 200 μL of DMSO, and the 
absorbance at 570 nM was measured using Victor-X3 multilabel reader 
(PerkinElmer, MA, USA). The cytotoxicity was expressed as percentage over 
control. 
3.2.3 DNA fragmentation analysis 
Cleavage of chromosomal DNA into oligonucleosomal fragments (180-200 
bp) by endonuclease called CAD is a distinctive feature of apoptosis in many cell 
types. The fragmented DNA can be detected by agarose gel electrophoresis 
followed by ethidium bromide staining. Leukemic cells (3.5×106 cells/plate), treated 
with various concentrations of SNG, were collected by centrifugation (600 g for 5 
min) and the pellets were washed with PBS, and re-suspended in 200 μL of lysis 
buffer (50 mM Tris-HCl, pH 7.5, 3% nonionic detergent IGEPAL CA-630, and 20 mM 
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EDTA) for 10 min. The samples were centrifuged (1000 g for 5 min) and 10 μL of 
20% SDS were added to the supernatant. RNA was digested using RNase A 
(40 μg/mL at 56°C for 2 h), followed by Proteinase K (40 μg/mL at 56°C for 2 h) to 
remove the proteins. The DNA was then precipitated with 0.1 vol of 3 M sodium 
acetate and 2.5 vol of ice-cold absolute ethanol. After centrifugation (13,500 g for 20 
min), the DNA pellets were washed with 70% ethanol and air-dried. The dried pellets 
were re-suspended in 20 μL TE buffer (10 mM Tris-HCl, pH 7.5, and 0.1 mM EDTA) 
and incubated at 65°C for 5 min. The re-suspended DNA was subjected to 
electrophoresis (constant voltage of 70 V for 2–3 h) on 1.8% agarose gel containing 
1 µg/mL ethidium bromide and photographed under UV transillumination. 
3.2.4 Fluorescein isothiocyanate (FITC) - Annexin V propidium iodide FACS 
analysis for apoptosis quantification 
During early apoptosis phosphatidylserine, which is normally found 
exclusively in the inner leaflet of the plasma membrane, translocates to the cell 
surface. This can be detected by using FITC (fluorochrome)-conjugated Annexin V, 
a phosphatidylserine binding protein. During the late phase of apoptosis, cells lose 
its membrane integrity which allow the staining of DNA with a fluorescent dye, 
propidium iodide (PI). By conducting FACS analysis using FITC-Annexin V and PI 
together, both early (annexin V-positive, PI-negative) and late (annexin V-positive 
and PI-positive) apoptotic cells can be identified and quantified. Annexin V-PI 
apoptosis measurement was performed according to the manufacturer’s protocol 
with slight modification. Briefly, SNG-treated cells (1×106 cells/plate) were washed 
twice with ice cold PBS and re-suspended in 1 mL of 1X binding buffer 
(10 mM HEPES, pH 7.4, 140 mM NaOH, and 2.5 mM CaCl2). To the 100 µL of re-
suspended solution, 3 µL of FITC-Annexin-V and 3 µL of PI were added. After 15 
min incubation at room temperature, 400 µL of binding buffer was added to each 
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tube and apoptosis was quantified by BD FACSCanto II and FACSDiva software 
(MA, USA). 
3.2.5 Enzymatic caspase-3 assay 
The assay is based on the hydrolysis of Ac-DEVD-pNA by caspase-3, 
resulting in the release of yellowish colored p-nitroaniline (pNA) moiety which can be 
measured at 405 nM. The assay was performed according to the kit manufacturer’s 
protocol with slight modification. Briefly, SNG treated cells (3.5×106 cells/plate) were 
washed twice with ice cold PBS and re-suspended in 200 µL of lysis buffer (50 mM 
HEPES, pH 7.4, 5 mM CHAPS, and 5 mM DTT). The cell lysates were centrifuged 
(20,000 g for 15 min), total protein content was determined (Bio-Rad protein assay), 
100 µg of protein was incubated (37°C for 90 min) with 10 µL of Ac-DEVD-pNA (20 
mM), and the volume was made up to 100 µL using assay buffer (20 mM HEPES, 
pH 7.4, 2 mM EDTA, 0.1% CHAPS, and 5 mM DTT). After the incubation, the 
absorbance was read using Victor-X3 multilabel plate reader. 
3.2.6 SDS-PAGE and Western blot analysis 
SDS-PAGE and Western blotting are used to detect specific protein in a 
given sample. In this technique, proteins are separated based on their molecular 
weight using SDS-PAGE, and then transferred on to a membrane. The membrane is 
then stained with labelled antibodies specific to the target protein, which can be then 
visualized as bands. By analyzing the mobility and intensity of the bands, expression 
details of target proteins in the sample could be identified. Leukemic cells 
(3.5×106 cells/plate) treated with SNG were collected by centrifugation (600 g for 5 
min). Pellets were washed twice with ice cold PBS and then re-suspended in 200 μL 
of RIPA lysis buffer (50 mM Tris HCl, pH 7.4, 1% IGEPAL CA-630, 40 mM NaF, 
10 mM NaCl, 10 mM Na3VO4, 1 mM PMSF, 10 mM DTT, and EDTA-free Rosh 
protease inhibitor tablets per 20 mL buffer). The cell lysates were centrifuged 
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(20,000 g for 15 min) and total protein content were determined (Bio-Rad protein 
assay), and the sample was prepared by mixing with 6X loading buffer and boiling at 
100°C for 3 min. Equivalent amount of proteins were resolved on a 7-15% SDS-
PAGE gel using Bio-Rad electrophoresis apparatus (Bio-Rad Laboratories, 
CA, USA). Following the electrophoresis, the proteins were transferred on to 
nitrocellulose membrane (Whatman, Little Chalfont, UK) by the wet transfer method 
using Bio-Rad electrotransfer apparatus (Bio-Rad Laboratories, CA, USA). The 
membranes were then blocked with 5% nonfat milk (in Tris buffer saline containing 
0.1% Tween 20), incubated with the desired primary antibodies (at room 
temperature for 2 h), followed by corresponding horseradish peroxidase (HRP)-
conjugated secondary antibodies (at room temperature for 1 h). The bands were 
then visualized using the enhanced chemiluminescence reagent (Thermo Scientific, 
MA, USA) according to the manufacturer’s protocols and recorded on Kodak 
BioMAX MR Film (Carestream Health, NY, USA).\ 
3.2.7 Intracellular measurement of reactive oxygen species 
2',7'-dichlorodihydrofluorescein diacetate is a cell-permeable fluorogenic 
probe retained intracellularly by cellular esterase-mediated deacetylation to 2’, 7’-
dichlorodihydrofluorescin (DCFH).  Upon oxidation by ROS, the non-fluorescent 
DCFH rapidly gets oxidized to a highly fluorescent 2’, 7’-dichlorofluorescein (DCF). 
The fluorescence intensity can be observed under fluorescence microscopy and 
measured using spectrophotometry. Leukemic cells were pre-incubated with 25 μM 
H2DCFDA for 30 min, washed twice with HBSS buffer, treated with SNG for 30 min, 
and washed again with HBSS buffer. Cells were then photographed under DP71 
fluorescent microscope (Olympus, Tokyo, Japan) and fluorescence intensity was 
quantitatively measured using Victor-X3 multilabel plate reader at 485 nM for 
excitation and at 535 nM for emission. 
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3.2.8 Amplex red assay for hydrogen peroxide 
Amplex Red, in the presence of HRP, reacts with H2O2 in a 1:1 stoichiometry 
to produce highly fluorescent resorufin which can be measured using 
spectrophotometry. The assay was performed according to the kit manufacturer’s 
protocol with slight modification. Briefly, leukemic cells (20,000 cells/well) grown in 
96 well black plates were incubated with 100 µL of reaction mixture (50 µM Amplex 
Red in DMSO, 100 µL of 0.1 U/mL HRP in Krebs–Ringer phosphate buffer, and 
required dose of SNG). The cells were incubated for 30 min in the dark, and 
fluorescence intensity was quantitatively measured using Victor-X3 multilabel reader 
at 540 nM for excitation and 590 nM for emission. 
3.2.9 Detection of mitochondrial hydrogen peroxide 
Mitochondria peroxy yellow 1 is a fluorescent probe that specifically localizes 
to the mitochondria and selectively respond to H2O2 by fluorescence enhancement. 
Mitochondrial-derived H2O2 was detected as described previously (Dickinson, Lin, & 
Chang, 2013) with slight modification. Briefly, leukemic cells (0.5×106 cells/well in 6 
well plates) were exposed to 10 µM of MitoPY1 for 1 h.  After the incubation, cells 
were centrifuged (600 g for 5 min), washed with PBS, and the medium was replaced 
with fresh medium containing SNG and inhibitors. Following a 30 min incubation, 
cells were washed with PBS and supplied with phenol red free RPMI. Changes in 
fluorescence was photographed using a DP71 fluorescent microscope (Olympus, 
Tokyo, Japan). 
3.2.10 Catalase activity assay 
Catalase reacts with methanol in the presence of H2O2 to form 
formaldehyde. The formaldehyde produced reacts with purpald (4-Amino-3-
hydrazino-5-mercapto- 1,2,4-triazole), and the adduct formed from the reaction is 
oxidized by potassium periodate under alkaline condition to give a purple colored 
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compound which can be measured using spectrophotometry. The assay was 
performed according to the kit manufacturer protocol with slight modification. Briefly, 
after SNG treatment, the cells (3.5×106 cells/plate) were collected by centrifugation 
(600 g for 5 min), washed with ice cold PBS, and homogenized in 200 µL of lysis 
buffer (50 mM K2HPO4, pH 7.0, and 1 mM EDTA). Cell lysates were centrifuged 
(20,000 g for 15 min), 20 µL of supernatants were incubated with 100 µL of assay 
buffer (100 mM K2HPO4, pH 7.0), 30 µL of methanol, and 20 µL of H2O2 (8.82 M) in 
a 96 well microtiter plate. The plate is then shaken for about 20 min, 30 µL of 
potassium hydroxide (10 M), and 30 µL of purpald were added. The plate is shaken 
for further 20 min, and 10 µL of potassium periodate was added to each well. After 5 
min incubation, absorbance was read at 540 nM using Victor-X3 multilabel plate 
reader. 
3.2.11 Determination of total glutathione 
The assay is based on the continuous reaction of GSH and 5,5’-dithiobis (2-
nitrobenzoic acid) (DTNB) to produce yellow colored 2-nitro-5-thiobenzoic acid 
(TNB) and glutathione disulfide (GSSG). The GSSG formed can be recycled back to 
GSH by GR in the presence of NADPH and the reaction is repeated to produce 
more yellow color which can be measured using spectrophotometry at 412 nM. The 
assay was performed according to the kit manufacturer’s protocol with slight 
modification. Briefly, after the SNG treatment, cells (3.5×106 cells/plate) were 
collected by centrifugation (600 g for 5 min), washed with ice cold PBS, 
deproteinized with 200 µL of 5% 5-Sulfosalicylic acid, and centrifuged (20,000 g for 
15 min) in order to remove the precipitated protein. Working mixture was prepared 
by adding 228 µL of the GR enzyme solution (6 units/mL) and 228 µL of DTNB stock 
solution (1.5 mg/mL) to 8 mL of assay buffer (100 mM K2HPO4 buffer, pH 7.0, and 1 
mM EDTA). The supernatant (20 µL) was incubated with 150 µL of working mixture, 
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and 50 µL of NADPH (0.16 mg/mL). Absorbance was read using Victor-X3 
multilabel plate reader. 
3.2.12 Intracellular ceramide measurement 
In this assay, ceramide was converted to sphingosine using CDase enzyme. 
The sphingosine formed is derivatized with OPA, which can be quantified using 
HPLC as described previously (Thayyullathil, Chathoth, Kizhakkayil, et al., 2011). 
Briefly, after the SNG treatment, cells (3.5×106 cells/plate) were collected by 
centrifugation (600 g for 5 min), washed in PBS, and lysed using ceramide assay 
lysis buffer (50 mM Tris, pH-7.4, and 0.4% IGEPAL CA 630) by freeze and thaw 
method. Lysate were heated at 70°C for 5 min in a water bath to precipitate the 
proteins, and centrifuged (20,000 g for 15 min) at 4oC. The reaction was started by 
incubating 10 μL of supernatant with 20 ng of recombinant human neutral 
ceramidase (nCDase) enzyme (10 μL) for 1 h at 37°C. During this incubation, any 
ceramide in the sample will be converted in to sphingosine. The reaction was 
stopped by adding 55 μL of stopping buffer (1:9; 0.07 M potassium hydrogen 
phosphate buffer: methanol). After stopping the reaction, the sphingosine formed 
was derivatized with OPA reagent (12.5 mg OPA dissolved in 250 μL ethanol and 
12.5 μL β-mercaptoethanol. The volume was made up to 12.5 mL with 3% w/v boric 
acid). The mixture was allowed to stand in the dark for 30 min and an aliquot of 
25 μL was analyzed by HPLC using Waters 1525 binary pump system, Waters 
XTerra C18 column (5 μM, 3 mM × 250 mM), and Waters 2475 fluorescence 
detector (Walters, MA, USA) at an excitation and emission wavelength of 340 nm 
and 455 nm, respectively. The mobile phase used was 20% methanol and 80% 1:9 
stopping buffer at a flow rate of 0.5 mL/min. 
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3.2.13 Assay for sphingomyelinase, ceramidase and glucosylceramide 
synthase activity 
The assay is based on the conversion of fluorescent 7-nitro-2-1,3-
benzooxadiazolyl amino-dodecanoic acid (NBD)-conjugated substrate by 
corresponding enzyme into NBD-conjugated product. The enzyme activity was 
measured as described previously (Thayyullathil, Chathoth, Hago, et al., 2011). 
Briefly, NBD-conjugated product was separated from remaining substrate using TLC 
on silica gel. The spot corresponding to the NBD-conjugated product were scraped, 
incubated with ethanol at 37°C for 5 min to extract the compounds from silica, and 
fluorescence intensity was quantitatively measured using Victor-X3 multilabel reader 
at 485 nM excitation and at 535 nM emission. 
Assays for aSMase and neutral sphingomyelinase (nSMase) activities were 
performed as previously described (Loidl, Claus, Deigner, & Hermetter, 2002; 
Taguchi et al., 2004; Zeidan et al., 2006) with slight modification. Briefly, after SNG 
treatment, cells (3.5×106 cells/plate) were collected by centrifugation (600 g for 5 
min), washed in PBS, and lysed using 200 µL of aSMase assay lysis buffer (250 
mM CH3COONa, pH 5.0, and 0.2% Triton X-100) and nSMase assay lysis buffer (10 
mM Tris–HCl, pH 7.5, 1 mM EDTA, 0.1% Triton X-100, 1 mM PMSF, 10 µg/mL 
pepstatin A, 0.15 U/mL aprotinin, and 50 µg/mL leupeptin) for corresponding 
enzyme activities. The cell lysates were centrifuged (20,000 g for 15 min), and total 
protein content were determined (Bio-Rad protein assay). Lysates normalized to 
equal total proteins (50 µg) were incubated with 50 µL of corresponding assay 
buffer. The assay buffer for different enzyme activities are: aSMase assay reaction 
buffer (0.1 M CH3COONa, pH 5, 10 µM C6-NBD-sphingomyelin, and 0.1% Triton X-
100) and nSMase assay reaction buffer (0.1 M Tris-HCl, pH 7.5, 10 µM C6-NBD-
sphingomyelin, 10 mM MgCl2, 0.1% Triton X-100, and 5 mM DTT). Final volume of 
0.1 mL was made using corresponding lysis buffer. The reaction mixture was 
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incubated at 37°C for 1 h. Reaction was stopped by addition of 90 µL of distilled 
water and 200 µL of chloroform/methanol (2:1, vol/vol). After properly mixing, the 
tubes were centrifuged at 1000 g for 5 min to separate the two phases. The lower 
organic phase was collected, dried in a speed vacuum concentrator (Savant 
Instruments, Hyderabad, India), and dissolved in 25 µL of chloroform/methanol (2:1, 
vol/vol). The sample (20 µL) were applied to the TLC plate and developed using 
chloroform/methanol/12 mM MgCl2 in distilled water (65:25:4, vol/vol) as solvent and 
the fluorescent intensity corresponding to the SMase-mediated conversion of C6-
NBD-sphingomyelin to C6-NBD-ceramide was quantified. 
Assay for GCS activity was performed using a similar method as described 
previously (Kizhakkayil et al., 2012; Taguchi et al., 2004) with slight modification. 
Briefly, after the treatment and harvesting, cells were lysed in 200 µL of GCS assay 
lysis buffer (20 mM Tris–HCl, pH 7.5, 10 mM EGTA, 2 mM EDTA, 1 mM PMSF, and 
2.5 μg/mL leupeptin) using a homogenizer. Lysates were centrifuged (1000 g for 5 
min at 4°C), supernatant normalized to equal total proteins (50 µg) were incubated 
(37°C for 2 h) with 25 µL of GCS assay reaction buffer (10 mM Tris-HCl, pH 7.5, 1 
mM EDTA, 10 µg/mL C6-NBD-ceramide, 100 µg/mL phosphatidylcholine, 500 µM 
UDP-glucose. Final volume of 0.1 mL using corresponding lysis buffer). The reaction 
was stopped by the addition of 90 µL of distilled water and 200 µL of 
chloroform/methanol (2:1, vol/vol). After properly mixing, the tubes were centrifuged 
at 10,000 g for 1 min to separate the two phases. The lower organic phase was 
collected, dried, and developed in similar way to the SMase activity assay and the 
fluorescent intensity corresponding to the GCS-mediated transfer of glucose residue 
from UDP-glucose to C6-NBD-ceramide was quantified. 
In the case of acid ceramidase (aCDase) and nCDase activity assay, after 
the treatment and harvesting, the cells were lysed in 200 µL of aCDase assay lysis 
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buffer (50 mM CH3COONa, 5 mM MgCl2, 1 mM EDTA, pH 4.5, and 0.5% Triton X-
100) or nCDase assay lysis buffer (50 mM Tris, pH 7.5, 5 mM EDTA, 0.5% Triton X-
100, 5 mM Cacl2, and 2mM PMSF). The cell lysates were centrifuged (20,000 g for 
15 min), lysates normalized to equal total proteins (50 µg) were incubated with 50 
µL of aCDase assay reaction buffer (100 µM D-erythro-C12-NBD-ceramide in 250 
mM CH3COONa, pH 5.0, and 0.2% IGEPAL-CA 6300) or nCDase assay reaction 
buffer (100 µM D-erythro-C12-NBD-ceramide in 50 mM Tris buffers, pH 7, and 0.3% 
Triton X-100). Final volume of 0.1 mL was made using corresponding lysis buffer. 
The reaction mixtures were incubated at 37°C for 1 h. The reaction was stopped by 
adding 100 μL of chloroform/methanol (1:1, vol/vol). The sample was dried, 
dissolved in 25 μL of chloroform/methanol (2:1, vol/vol), applied to a TLC plate, and 
developed using chloroform, methanol, and ammonia (75:15:0.9, vol/vol). 
Fluorescent intensity corresponding to the conversion of C12-NBD-ceramide to 
NBD-dodecanoic acid was quantified. 
3.2.14 Statistical analysis 
Statistical analysis was performed using Graph pad Prism 5.0 software. Data 
are shown as mean ± standard deviation. Significance was analyzed by one-way 
anova using Bonferroni post hoctest. A difference was considered significant when 
p<0.05. p<0.05 (*); p<0.01 (**); p<0.001 (***). 
55 
 
 
 
 
Chapter 4: Results and findings 
 
4.1 Sanguinarine induces growth arrest and apoptosis in human leukemic 
cells 
The primary objective of this study was to determine the intracellular 
mechanisms by which SNG inhibits proliferation and induces cell death in human 
leukemic cells. To systematically address the inhibitory effect of SNG on human 
leukemic cells, viability was evaluated by MTT assay following the SNG treatment. 
As shown in Fig. 4.1.A and B, SNG treatment resulted in a significant dose- and 
time-dependent growth inhibition in both Jurkat and Molt-4 cells. 
A      B 
 
Figure 4.1. Sanguinarine induces loss of viability in human leukemic cells. (A) 
Leukemic cells were treated with the indicated concentration of SNG for 4 h, (B) 
Jurkat and Molt-4 cells were treated with 3 μM and 1.5 μM SNG, respectively, for 
the indicated time period. Cell viability was assessed. Data shown are means ± SD 
(n=3) (***p<0.001 vs control). 
 
Several lines of evidence indicate that SNG induces apoptotic cell death in a 
variety of cancer models (Adhami et al., 2004; Choi et al., 2008; Jang et al., 2009; J. 
S. Lee et al., 2012; Rosen et al., 2015).  To determine whether SNG-induced loss of 
viability was as a result of apoptosis, two of the defining characteristics of apoptosis 
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such as plasma membrane blebbing and DNA fragmentation were evaluated 
following SNG treatment. As shown in Fig 4.2.A, in response to SNG treatment, 
some of the cells showed membrane blebbing as observed under an inverted 
microscope. In line with this, treatment with SNG also resulted in the appearance of 
“DNA ladder” fragmentation pattern (Fig. 4.2.B), indicating that SNG induces 
apoptosis in human leukemic cells. Cell surface exposure of phosphatidylserine is a 
classic feature of cells undergoing apoptosis, which can be detected by using 
Annexin V-FITC. During the late phase of apoptosis, cell loses its membrane 
integrity which allows the entry of PI, a DNA-binding fluorescent dye. By conducting 
FACS analysis using FITC-Annexin V and PI together, both early and late phase of 
apoptotic cells can be identified and quantified. To quantitatively analyze SNG-
induced apoptotic cell death, Annexin V-FITC/PI staining followed by flow cytometry 
analysis was performed. As shown in Fig. 4.2.C, significant increase in apoptosis 
was observed in cells treated with increasing concentrations of SNG. 
A     B       
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C 
Figure 4.2. Sanguinarine induces apoptosis in human leukemic cells. (A) Jurkat cells 
were treated with 3 μM and Molt-4 cells were treated with 1.5 μM SNG for 4 h.  
Images were taken under an inverted phase-contract microscope. Blebs are 
indicated with arrows. (B) Leukemic cells were treated with the indicated 
concentration of SNG for 4 h and DNA fragmentation assay was performed. (C) 
Cells treated with the indicated concentrations of SNG for 4 h, were stained with 
Annexin V-FITC/PI, and apoptosis was quantified using FACS analysis. Each 
quadrant represent cells in different stages; Q3 viable, Q4 early apoptosis, Q2 late 
apoptosis, and Q1 necrosis. 
Both caspase-dependent and -independent mechanisms have been ascribed 
to the membrane blebbing. For instance, membrane blebbing may be mediated by 
DAPK via caspase-independent mechanism or by caspase-dependent cleavage of 
PAK2, gelsolin, and ROCK I (Fischer et al., 2003; U. Ziegler & Groscurth, 2004). 
Similarly, DNA fragmentation may be mediated by caspase-dependent cleavage of 
ICAD or by EndoG and AIF via caspase-independent mechanism (Fischer et al., 
2003; Saraste & Pulkki, 2000). Cell surface exposure of phosphatidylserine can also 
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occur via caspase-dependent and –independent mechanisms (Fischer et al., 2003; 
Saraste & Pulkki, 2000). However, in most instances, apoptosis is initiated and 
executed by caspases. Next, we explored whether SNG-induced apoptosis was 
associated with caspase activation. Western blot analysis revealed that SNG 
treatment markedly increased the formation of active forms of cleaved caspase-8, -
9, and -3 (Fig. 4.3.A). Consistently, the cleavage of caspase-3 substrate PARP was 
also increased in a dose- and time-dependent manner in SNG-treated cells (Fig. 
4.3.B). Quantitative analysis of caspase-3 activation was also carried out as 
described in the materials and methods. Treatment with SNG prominently increases 
the activity of caspase-3 in both leukemic cells (Fig. 4.3.C). 
A 
 
B 
 
 
 
 
 
 
59 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Sanguinarine induces caspase-dependent apoptosis in human leukemic 
cells. (A) Jurkat and Molt-4 cells were treated with 3 μM and 1.5 μM SNG, 
respectively, for the indicated time period. After the treatment, Western blot analysis 
of caspase-8, -9, and -3 was performed. (B) Leukemic cells were treated with the 
indicated concentration of SNG for 4 h (upper panel), and Jurkat cells were treated 
with 3 μM and Molt-4 cells were treated with 1.5 μM SNG for the indicated time 
period (lower panel). PARP cleavage was analyzed by Western blot. Actin was used 
as a loading control (C) Jurkat and Molt-4 cells were treated with 3 μM and 1.5 μM 
SNG, respectively, for the indicated time period. Caspase-3 assay was performed. 
Data shown are means ± SD (n=3) (***p<0.001 vs control). 
 
To confirm the role of caspases in SNG-induced apoptosis, cells were pre-
treated with pan caspase inhibitor, Z-VAD-FMK and examined for apoptosis and 
cellular viability. Pre-treatment with Z-VAD-FMK significantly abolished SNG-
induced caspase-3 activation (Fig. 4.4.A), apoptosis (Fig. 4.4.B and C), and loss of 
viability (Fig. 4.4.D), clearly demonstrating the role of caspase in SNG-induced 
apoptosis in human leukemic cells.  
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Figure 4.4. Caspase inhibitor attenuates SNG-induced apoptosis in human leukemic 
cells. Cells were pre-treated with 50 µM Z-VAD-FMK for 1 h followed by SNG (3 μM 
for Jurkat and 1.5 μM for Molt-4) treatment for 4 h. Following the treatment, (A) 
caspase-3 activity was measured. Data shown are means ± SD (n=3) (***p<0.001), 
(B) PARP cleavage was analyzed by Western blot. Actin was used as a loading 
control, (C) apoptosis was quantified using FACS analysis. Each quadrant represent 
cells in different stages; Q3 viable, Q4 early apoptosis, Q2 late apoptosis, and Q1 
necrosis, and (D) cell viability was assessed by MTT assay. Data shown are means 
± SD (n=3) (***p<0.001). 
 
The process of apoptosis is negatively regulated by IAPs that inhibit 
apoptosis and promote resistance to chemotherapy via caspase-dependent and –
independent mechanisms (Ceballos-Cancino et al., 2007; Dohi et al., 2007; Gyrd-
Hansen & Meier, 2010). SNG was shown to inhibit the expression of IAPs namely 
cIAP-1, cIAP-2, XIAP, and survivin in human leukemic cells (Fig. 4.5). Expression of 
cIAP-2 in Molt-4 was not altered following SNG-treatment (Fig. 4.5). Thus, our 
results suggest that down-regulation of anti-apoptotic proteins is another mechanism 
by which SNG could induce apoptosis in human leukemic cells. 
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Figure 4.5. Sanguinarine induces inhibition of IAP proteins in human leukemic cells. 
Jurkat and Molt-4 cells were treated with 3 μM and 1.5 μM SNG, respectively, for 
the indicated time period. Western blot analysis of the indicated proteins were 
carried out. Actin was used as a loading control. 
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4.2 Sanguinarine-induced reactive oxygen species generation is critical for the 
induction of apoptosis 
A large number of anticancer agents effectively kill cancer cells via 
increasing ROS generation or impeding the antioxidant defense mechanism (Miki et 
al., 2012; Thayyullathil, Chathoth, Hago, Patel, & Galadari, 2008; Thayyullathil, 
Rahman, Pallichankandy, Patel, & Galadari, 2014; Tsang, Chau, Kong, Fung, & 
Kwok, 2003; Woo et al., 2002). Previously, several reports have provided evidence 
for the role of ROS in the induction of apoptosis in response to SNG treatment 
(Dong et al., 2013; S. Kim et al., 2008; Matkar et al., 2008a, 2008b; Yin, Kim, Moon, 
& Lee, 2005). To the contrarily, some authors have observed that SNG-induced 
cytotoxicity is not associated with ROS generation (Debiton et al., 2003; Slunská, 
Gelnarová, Hammerová, Táborská, & Slaninová, 2010). Therefore, the second 
objective of our study was to investigate the role of ROS generation in SNG-induced 
apoptosis in human leukemic cells. To examine this, ROS generation was analyzed 
in SNG-treated cells by performing H2DCFDA staining followed by fluorescent 
microscopy. Treatment of leukemic cells with SNG resulted in the generation of 
H2DCFDA-derived fluorescence, as observed under a fluorescent microscope (Fig. 
4.6.A), suggesting that SNG induces ROS generation. Simultaneously, fluorescent 
intensity was quantitatively measured spectrophotometrically. A dose-dependent 
increase in H2DCFDA-derived fluorescence intensity was observed in both leukemic 
cell lines following SNG treatment (Fig. 4.6.B). 
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Figure 4.6. Sanguinarine induces intracellular reactive oxygen species generation in 
human leukemic cells. (A) Jurkat and Molt-4 cells were treated with 3 μM and 1.5 
μM SNG, respectively, for 30 min. ROS-mediated H2DCFDA-derived fluorescence 
was observed under fluorescent microscopy. H2O2 (300 µM) was used as a positive 
control. (B) H2DCFDA-derived fluorescence was quantified in leukemic cells treated 
with indicated concentration of SNG. Data shown are means ± SD (n=3) (*p<0.05 
and ***p<0.001 vs control). 
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In order to establish the role of ROS in SNG-induced apoptosis, both 
leukemic cells were pre-treated with thiol-based ROS scavengers, namely GSH and 
NAC, prior to treatment with SNG. GSH is the major non-protein thiol antioxidant, 
which directly removes ROS or may act as a substrate for GPx and Prx antioxidant 
system. The rate-limiting step in the GSH synthesis is the availability of cysteine. 
NAC provides an alternate means of boosting intracellular GSH via elevating the 
intracellular cysteine pools (Lushchak, 2012). Pre-treatment with both ROS 
scavengers significantly attenuated SNG-induced ROS generation (Fig. 4.7.A), 
apoptosis as analyzed by Annexin V-FITC/PI staining and Western blot analysis of 
PARP (Fig. 4.7.B and C), and loss of viability as measured by MTT assay (Fig. 
4.7.D). Moreover, other well-established thiol- and non-thiol-ROS scavengers such 
as α-lipoic acid and L-ascorbic acid also significantly reduced SNG-induced loss of 
viability (Fig. 4.7.E).  
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Figure 4.7. Sanguinarine induces reactive oxygen species-dependent apoptosis in 
human leukemic cells. Cells were pre-treated with GSH (10 mM) and NAC (10 mM) 
for 1 h followed by SNG (3 μM for Jurkat and 1.5 μM for Molt-4) treatment. Following 
the treatment (A) H2DCFDA-derived florescence was analyzed by fluorometry. Data 
shown are means ± SD (n=3) (***p<0.001), (B and C) apoptosis was evaluated by 
Western blot analysis of PARP and Annexin V-FITC/PI staining, and (D) cell viability 
was analyzed by using MTT assay. Data shown are means ± SD (n=3) (**p<0.01 
and ***p<0.001). (E) Cells were pre-treated with L-ascorbic acid (50 μM) and α-lipoic 
acid (50 μM) for 1 h followed by SNG (3 μM for Jurkat and 1.5 μM for Molt-4) 
treatment for 4 h. Following the treatment, cell viability was measured by using MTT 
assay. Data shown are means ± SD (n=3) (**p<0.01 and ***p<0.001) 
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H2DCFDA-based fluorescence generation is non-specific for a particular kind 
of ROS. In order to distinguish the type of ROS generated by SNG, the effect of 
SNG in the presence of Sod Pyr and catalase (H2O2 scavengers), and SOD (O2•− 
scavenger) was tested. As shown in Fig. 4.8.A and B, pre-treatment with H2O2 
scavengers significantly inhibited the enhancement of H2DCFDA-derived 
fluorescence and loss of viability caused by SNG, while O2•− scavenger failed to do 
so. To confirm H2O2 generation further, Amplex red, a H2O2-specific fluorogenic 
probe was used. As shown in Fig. 4.8.C, SNG treatment of Jurkat cells resulted in a 
significant increase of Amplex red-derived fluorescence. Specific H2O2 scavengers 
such as catalase and Sod Pyr significantly abolished SNG-induced fluorescence 
generation (Fig. 4.8.C). Together, these data suggest that ROS plays a critical role 
in SNG-induced apoptosis in human leukemic cells. Since, Sod Pyr and catalase are 
specific scavengers for H2O2, these observations provide a strong basis for the 
involvement of H2O2 in SNG-induced apoptosis.  
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Figure 4.8. Sanguinarine induces hydrogen peroxide-dependent cell death in human 
leukemic cells. (A) Cells were pre-treated with Sod Pyr (500 µM) and SOD (1000 
U/mL) for 1 h followed by SNG (3 μM for Jurkat and 1.5 μM for Molt-4) treatment for 
4 h. H2DCFDA-derived florescence was analyzed by fluorometry. Data shown are 
means ± SD (n=3) (***p<0.001 and ns: not significant). (B) Cells were pre-treated 
with Sod Pyr (500 µM), catalase (catalase (5000 U/mL), and SOD (1000 U/mL) for 1 
h followed by SNG (3 μM for Jurkat and 1.5 μM for Molt-4) treatment for 4 h. Cell 
viability was analyzed by MTT assay. Data shown are means ± SD (n=3) (*p<0.05, 
***p<0.001, and ns: not significant). (C) Jurkat cells pre-treated with Sod Pyr (500 
µM) and catalase (5000 U/mL) were exposed to 3 μM SNG and 50 μM Amplex red. 
Amplex red-derived florescence was analyzed by fluorometry. Data shown are 
means ± SD (n=3) (***p<0.001). 
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The mitochondrial respiratory chain is a major source of ROS production 
within most mammalian cells (Sena & Chandel, 2012). MitoPY1 is a mitochondria-
specific fluorescent probe that selectively responds to H2O2 by fluorescence 
enhancement. To determine whether SNG induces mitochondrial-derived H2O2, 
MitoPY1 was used. When leukemic cells were induced to undergo apoptosis by 
SNG, elevated levels of MitoPY1-derived fluorescence was observed, and this 
increase was significantly reduced by Sod Pyr and catalase (Fig. 4.9). Similar 
results were observed in H2O2-treated cells which was used as a positive control 
(Fig. 4.9). 
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Figure 4.9. Sanguinarine induces mitochondrial-hydrogen peroxide generation in 
human leukemic cells. Fluorescent microscopy images were taken of Jurkat cells 
pre-treated with 10 µM MitoPY1 followed by SNG (3 µM) treatment in the presence 
and absence of Sod Pyr (500 µM) and catalase (5000 U/mL). H2O2 (300 µM) was 
used as a positive control. FL, fluorescence; PC, phase contrast. 
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Catalase is an important antioxidant enzyme that catalyzes the dissociation 
of H2O2 directly into H2O and O2 (Scibior & Czeczot, 2006). Accumulation of H2O2 
due to catalase suppression has been implicated in the apoptosis of a variety of 
cancers, including cervix, ovarian, and lung cancer (Iwai et al., 2003; Yang et al., 
2011). Simultaneously, catalase has been shown to protect tumor cells from ROS-
mediated apoptosis (Bechtel & Bauer, 2009). In this context, enzymatic activity of 
catalase was measured following SNG treatment. As shown in Fig. 4.10, catalase 
enzymatic activity was significantly reduced upon SNG treatment in Jurkat cells by 
four hours post treatment. 
 
 
 
 
 
 
 
    
 
 
Figure 4.10. Sanguinarine decreases catalase enzymatic activity. Jurkat cells were 
treated with 3 µM SNG for the indicated time period and catalase activity was 
measured. Data shown are means ± SD (n=3) (*p<0.05 and ***p<0.001 vs control). 
 
Depletion of intracellular GSH is considered as an early hallmark of H2O2-
mediated oxidative stress, and a prime signaling event associated with the induction 
of apoptotic cell death (Franco & Cidlowski, 2009). Treatment of leukemic cells with 
different doses of SNG resulted in a dose-dependent decrease in cellular GSH 
content (Fig. 4.11.A). In order to examine if H2O2 generation is responsible for the 
observed GSH depletion, cells were pre-treated with catalase followed by SNG 
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treatment and cellular GSH level was quantified. As shown in Fig. 4.11.B, 
scavenging of H2O2 using catalase significantly inhibited the GSH depletion, 
suggesting that SNG-induced H2O2 generation leads to the intracellular GSH 
depletion.  
 
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
Figure 4.11. Sanguinarine induces hydrogen peroxide-dependent glutathione 
depletion. (A) GSH content were measured in leukemic cells treated with indicated 
concentration of SNG for 4 h. Data shown are means ± SD (n=3) (*p<0.05, 
**p<0.01, and ***p<0.001 vs control) (B) Cells pre-treated with catalase (5000 U/mL)  
were treated with SNG (3 μM for Jurkat and 1.5 μM for Molt-4), and examined for 
total GSH content. Data shown are means ± SD (n=3) (*p<0.05 and ***p<0.001). 
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4.3 Sanguinarine induces reactive oxygen species-dependent ceramide 
generation in human leukemic cells 
Previously, we and others have established that ceramide is an important 
pro-apoptotic lipid activated in response to various anticancer agents (Galadari et 
al., 2015; Pettus, Chalfant, & Hannun, 2002; Thayyullathil, Chathoth, Kizhakkayil, et 
al., 2011; Yabu et al., 2015). In addition, a growing body of evidence suggests that 
ROS enhances ceramide generation through modulating ceramide biosynthetic and 
degradative enzymes (Galadari et al., 2013). Therefore, the third objective of our 
study was to elucidate the role of ceramide in SNG-induced cell death. Initially, we 
investigated whether ceramide is generated upon SNG treatment in leukemic cells. 
As shown in Fig. 4.12.A and B, SNG treatment resulted in a significant dose- and 
time-dependent induction of ceramide in both leukemic cell lines.  
A      B 
  
Figure 4.12. Sanguinarine induces ceramide generation in human leukemic cells. 
(A) Cells were treated with indicated concentration of SNG for 4 h, (B) Jurkat and 
Molt-4 cells were treated with 3 μM and 1.5 μM SNG, respectively, for the indicated 
time period. Ceramide levels were measured as described in the Materials and 
methods. Data shown are means ± SD (n=3) (*p<0.05, **p<0.01, and ***p<0.001 vs 
control). 
 
As mentioned earlier, a plethora of studies have demonstrated that ROS 
induces ceramide generation, and once generated, both of them contribute to 
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apoptosis induction (Dumitru, Zhang, Li, & Gulbins, 2007; Galadari et al., 2013; 
Thayyullathil et al., 2014). Since, SNG induces both ROS generation and ceramide 
accumulation, the possibility of ROS-induced ceramide generation was examined. 
Pre-treatment with GSH and NAC completely abrogated ceramide accumulation in 
Jurkat and Molt-4 cells, as depicted in Fig. 4.13.A and 4.13.B, respectively. This 
data clearly demonstrate that SNG induces ROS-dependent ceramide generation in 
both Jurkat and Molt-4 human leukemic cells. 
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Figure 4.13. Sanguinarine induces ROS-dependent ceramide generation in human 
leukemic cells. (A) Jurkat and (B) Molt-4 cells were pre-treated with GSH (10 mM) 
and NAC (10 mM) for 1 h, followed by the SNG treatment (3 μM for Jurkat and 1.5 
µM for Molt-4) for 4 h. Ceramide levels were measured as described in the Materials 
and methods. Data shown are means ± SD (n=3) (**p<0.01 and ***p<0.001) 
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Extracellular addition of H2O2 may be used to mimic the effects of 
intracellularly produced ROS (Y. Chen, Azad, & Gibson, 2009). In order to further 
confirm the involvement of ROS in SNG-induced ceramide generation and 
apoptosis, Jurkat cells were treated with 400 µM H2O2 for 12 h. As expected, H2O2 
treatment resulted in an increase in ceramide generation (Fig. 4.14.A), apoptosis 
(Fig. 4.14.B), and loss of cell viability (Fig. 4.14.C).   
 
A     B 
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Figure 4.14. Effect of hydrogen peroxide on ceramide generation and apoptosis. 
Jurkat cells were treated with 400 μM H2O2 for 6 h. Following treatment, (A) 
ceramide levels were measured by HPLC, (B) PARP cleavage was analyzed by 
Western blot, and (C) cell viability was measured by using MTT assay. Data shown 
are means ± SD (n=3) (*p<0.05 and ***p<0.001 vs control). 
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 Ceramide can be generated in the cells either via de novo synthesis, or via 
sphingomyelin hydrolysis (Galadari et al., 2013; Galadari et al., 2015). In order to 
distinguish which of these pathways is involved in SNG-induced ceramide 
generation, and to decipher whether the ceramide that is generated has any role in 
SNG-induced loss of viability, leukemic cells were pre-treated with inhibitors 
targeting these pathways prior to SNG treatment, and the cells were analyzed for 
ceramide generation and viability. The de novo ceramide synthesis inhibitors (Myr 
and FB1) (Fig. 4.15.A and B), and the nSMase inhibitor (GW4869) (Fig. 4.15.C and 
D) had no effect on SNG-induced ceramide generation and loss of viability. 
Interestingly, aSMase inhibitor (Desip), partly, but significantly, blocked the SNG-
induced ceramide generation and loss of viability in Jurkat cells, but not in Molt-4 
cells (Fig. 4.15.C and D). The reason for this disparity may well be due to the fact 
that Molt-4 cells have very little aSMase activity (B. Liu & Hannun, 1997). Moreover, 
Desip significantly protected SNG-induced apoptosis in Jurkat cells (Fig. 4.15.E), 
when none of the other inhibitors, namely Myr, FB1, and GW4869 produced any 
protection (Fig. 4.15.F, G, and H). Increase in the activity of aSMase was further 
confirmed by measuring its enzymatic activation following SNG treatment in Jurkat 
cells, while no change in the aSMase enzymatic activity was observed in Molt-4 
cells (Fig. 4.15.I). SNG had no effect on nSMase activity in both Jurkat and Molt-4 
cells (Fig. 4.15.J). Altogether, these data clearly demonstrate that SNG induces 
aSMase activation, leading to ceramide generation and subsequent induction of 
apoptosis, at least in Jurkat cells. In Molt-4 cells, SNG-induced ceramide generation 
was not mediated via aSMase activation. Moreover, the results also demonstrate 
that SNG has no effect on the activation of de novo ceramide biosynthetic enzymes 
(SPT and ceramide synthase) and nSMase enzyme in both Jurkat and Molt-4 cells. 
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Figure 4.15. Sanguinarine modulates the activity of ceramide biosynthetic enzymes. 
Cells were pre-treated with Myr (5 µM) and FB1 (50 µM) for 1 h, followed by 
incubation with SNG (3 μM for Jurkat and 1.5 μM for Molt-4) for 4 h. (A) Ceramide 
levels were measured as described in the Materials and methods and (B) cell 
viability was measured by using MTT assay. Data shown are means ± SD (n=3) 
(**p<0.01, ***p<0.001, and ns: not significant). Cells were pre-treated with GW4869 
(25 µM) and Desip (10 µM) for 1 h, followed by incubation with SNG (3 μM for Jurkat 
and 1.5 μM for Molt-4) for 4 h. (C) Ceramide levels were measured as described in 
the Materials and methods and (D) cell viability was measured by using MTT assay. 
Data shown are means ± SD (n=3) (*p<0.05, **p<0.01, ***p<0.001, and ns: not 
significant). Jurkat cells were pre-treated with (E) Desip (10 µM), (F) Myr (5 µM), (G) 
FB1 (50 µM), and (H) GW4869 (25 µM)   for 1 h, followed by incubation with 3 μM 
SNG for 4 h. Western blot analysis of PARP was carried out. Actin was used as 
loading control. Cells were treated with SNG (3 µM for Jurkat and 1.5 µM for Molt-4) 
for indicated time period. The activity of (I) aSMase and (J) nSMase were performed 
as described in the Materials and methods. Data shown are means ± SD (n=3) 
(*p<0.05 and ***p<0.001 vs respective control). 
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Next, to determine whether SNG modulate activity of ceramide degradative 
enzymes, we studied activities of ceramide degradative enzymes such as aCDase, 
nCDase, and GCS following SNG treatment. As shown in Fig. 4.16.A and B, 
activities of both aCDase and GCS were decreased in time-dependent manner in 
both Jurkat (Fig. 4.16.A) and Molt-4 (Fig. 4.16.B) cells, while nCDase activity was 
not altered in either cell lines. It is noteworthy that the GCS inhibition was highly 
significant and happened within 1 h of SNG treatment in both leukemic cells. These 
finding imply that inactivation of GCS and aCDase might play an important role in 
SNG-mediated apoptosis, and thus, we hypothesized that inhibition of these 
enzymes might enhance the cytotoxic activity of SNG. To test this hypothesis, Jurkat 
cells pre-treated with GCS inhibitor (PDMP) or aCDase inhibitor (NOE) and were 
subjected to SNG treatment. Following the treatment, cells were examined for 
ceramide generation, apoptosis and cell viability. Pre-treatment with both PDMP and 
NOE, followed by treatment with modestly toxic concentration of SNG resulted in a 
pronounced increase in ceramide generation (Fig. 4.16.C), PARP cleavage (Fig. 
4.16.D), and loss of viability (Fig. 4.16.E).  
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Figure 4.16. Sanguinarine modulates the activity of ceramide degradative enzymes. 
(A) Jurkat cells were treated with 3 µM SNG and (B) Molt-4 cells were treated with 
1.5 µM SNG for the indicated time period. Activity of nCDase, aCDase, and GCS 
were performed as described in the Materials and methods. Data shown are means 
± SD (n=3) (*p<0.05, **p<0.01, and ***p<0.001 vs respective control). Jurkat cells 
were pre-treated with PDMP (30 µM) and NOE (50 µM) for 1 h, followed by 
incubation with 2 μM SNG. After the treatment, (C) ceramide levels were measured. 
Data shown are means ± SD (n=3) (**p<0.01, and ***p<0.001), (D) Western blot 
analysis of PARP was carried out. Actin was used as loading control, and (E) cell 
viability was measured. Data shown are means ± SD (n=3) (**p<0.01, and 
***p<0.001) 
 
From the previous results, it is clear that SNG induces aSMase activity in 
Jurkat cells, while it inhibits aCDase and GCS activity in both Jurkat and Molt-4 
cells. To examine if these modulations are ROS-dependent, the activities of these 
enzymes were measured following NAC pre-treatment. Blockade of SNG-induced 
ROS generation by NAC essentially abrogated the activation of aSMase in Jurkat 
cells (Fig. 4.17.A) and inactivation of aCDase and GCS in both leukemic cells (Fig. 
4.17.A and B). Altogether, these results highlight the pivotal role of ROS-dependent 
ceramide generation in regulating the apoptotic action of SNG in human leukemic 
cells.  
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Figure 4.17. Sanguinarine induces reactive oxygen species-dependent modulation 
of ceramide biosynthetic and degradative enzyme activities. (A) Jurkat and (B) Molt-
4 cells were pre-treated with NAC (10 mM) for 1 h, followed by SNG (3 μM for Jurkat 
and 1.5 μM for Molt-4) treatment for 4 h. Following the treatment, activity of 
indicated enzymes (aSMase, aCDase, and GCS) were performed as described in 
the Materials and methods. Data shown are means ± SD (n=3) (*p<0.05, **p<0.01, 
and ***p<0.001) 
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4.4 Sanguinarine inhibits Akt signaling pathway downstream to the reactive 
oxygen species-dependent ceramide generation 
Akt is one of the most important and versatile protein kinase involved in the 
regulation of multiple tumorigenic cellular processes such as proliferation, cell cycle 
progression, inhibition of apoptosis, induction of cell motility, angiogenesis and 
metastasis (Brazil et al., 2002; Qiao et al., 2008). Akt inhibits apoptosis through 
direct phosphorylation and inactivation of pro-apoptotic proteins, down-regulation of 
pro-apoptotic proteins, and increased expression of anti-apoptotic proteins. Because 
Akt is deregulated in a wide range of malignancies, it is considered a major potential 
target for novel anticancer therapies (Brazil et al., 2002). Simultaneously, many 
compounds such as perifosine, MK2206, GDC-0068, and GSK2110183 that target 
Akt signaling pathway are in clinical trial or in the development pipeline (Dienstmann 
et al., 2014). Considering the fact that mutation and aberrant activation of PI3K/Akt 
signaling pathway are frequent in acute leukemia (Fransecky, Mochmann, & Baldus, 
2015), the fourth objective of our study was to examine the role of Akt in SNG-
induced apoptosis in human leukemic cells. Thus, we investigated whether SNG has 
any effect on phosphorylation (activation)-dephosphorylation (inactivation) status of 
Akt. As shown in Fig. 4.18.A and B, Akt is constitutively phosphorylated at Ser473 in 
the untreated leukemic cells. However, SNG treatment resulted in both a dose- and 
a time-dependent dephosphorylation of Akt at Ser473 (Fig. 4.18.A and B).  
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Figure 4.18. Sanguinarine induces Akt dephosphorylation at Ser473. (A) Leukemic 
cells were treated with indicated concentration of SNG for 4 h, (B) Jurkat and Molt-4 
cells were treated with 3 μM and 2 μM SNG, respectively, for the indicated time 
period. Western blot analysis for phospho-Akt Ser473, and total Akt was carried out.  
 
Sanguinarine-induced Akt dephosphorylation is not associated with changes 
in its upstream kinases, as evidenced by no changes in the expression of PI3K (both 
the regulatory subunit p85 and the catalytic subunit p110β), and phospho PDK1 
Ser241 in both leukemic cells following SNG treatment (Fig. 4.19).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19. Sanguinarine-induced Akt dephosphorylation is not associated with 
changes in its upstream kinase. Jurkat and Molt-4 cells were treated with 3 μM and 
2 μM SNG, respectively, for the indicated time period. Western blot analysis for 
PI3K p85, PI3K p110, phospho-PDK1 Ser241, and PDK1 was carried out.  
 
Meanwhile, Akt downstream kinases, such as mTOR and GSK3β, were 
dephosphorylated following exposure of leukemic cells to SNG (Fig. 4.20). It is well 
established that mTOR itself is an important cell growth and pro-survival protein that 
is activated by Akt-mediated phosphorylation at Ser2448, whereas, GSK3β mainly 
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acts as a pro-apoptotic protein that is inactivated by Akt-mediated Ser9 
phosphorylation (Ciuffreda, Di Sanza, Incani, & Milella, 2010; Jacobs et al., 2012; 
Manning & Cantley, 2007; Pópulo, Lopes, & Soares, 2012). Moreover, mTOR 
downstream target 4EBP1, was also dephosphorylated at Thr37/46 following SNG 
treatment of leukemic cells (Fig. 4.20). These results clearly demonstrate that SNG 
inhibits Akt signaling pathway, which is reported to be highly activated during the 
development and progression of leukemia (Fransecky et al., 2015; Okumura et al., 
2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20. Sanguinarine induces dephosphorylation of kinases downstream of Akt. 
Jurkat and Molt-4 cells were treated with 3 μM and 2 μM SNG, respectively, for the 
indicated time period. Western blot analysis for indicated proteins were carried out. 
Actin was used as loading control. 
 
In order to determine whether Akt dephosphorylation is ROS-dependent, 
leukemic cells pre-treated with GSH and NAC were treated with SNG, and 
monitored for Akt phosphorylation status. As shown in Fig. 4.21, both ROS 
scavengers significantly abrogated SNG-induced Akt dephosphorylation in both 
Jurkat and Molt-4 cells, demonstrating that Akt dephosphorylation is a ROS-
dependent process.  
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Figure 4.21. Sanguinarine induces reactive oxygen species-dependent Akt 
dephosphorylation in human leukemic cells. Cells were pre-treated with GSH (10 
mM) and NAC (10 mM) for 1 h, followed by SNG treatment (3 μM for Jurkat and 2 
μM for Molt-4) for 4 h. Western blot analysis for phospho-Akt Ser473, and total Akt 
was carried out. 
 
Next, an attempt was made to determine whether Akt dephosphorylation is 
downstream to the ROS-induced ceramide generation. Pre-treatment with Desip, 
which had previously shown to inhibit SNG-induced ceramide generation and 
apoptosis (Fig. 4.15.C, D, and E), also blocked SNG-induced Akt dephosphorylation 
(Fig. 4.22.A). Furthermore, de novo ceramide biosynthetic enzymes inhibitors (Myr 
and FB1) and the nSMase inhibitor (GW4869), did not inhibit SNG-induced Akt 
dephosphorylation (Fig. 4.22.B). These inhibitors had previously shown to have no 
effect on SNG-induced ceramide generation, loss of viability and apoptosis (Fig. 
4.15.A, B, F, G and H). Moreover, pre-treatment with PDMP or NOE, which had 
previously shown to sensitize SNG-induced ceramide generation and apoptosis 
(Fig. 4.16.C, D, and E), also sensitized SNG-induced Akt dephosphorylation (Fig. 
4.22.C).  
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Figure 4.22. Sanguinarine induced Akt dephosphorylation is downstream to the 
reactive oxygen species-dependent ceramide generation. Jurkat cells were pre-
treated with (A) Desip (10 µM), and (B) Myr (5 µM), FB1 (50 µM), and GW4869 (25 
µM) for 1 h, followed by 3 µM SNG treatment for 4 h. Following the treatment, 
Western blot analysis for phospho-Akt Ser473, and total Akt was carried out. (C) 
Jurkat cells were pre-treated with PDMP (30 µM) and NOE (50 µM) for 1 h, followed 
by the 2 µM SNG treatment for 4 h. Following the treatment, Western blot analysis 
for phospho-Akt Ser473, and total Akt was carried out. 
 
These data clearly indicate that SNG induces Akt-dephosphorylation 
downstream to the ROS-induced ceramide generation. In order to confirm this 
further, Jurkat cells were treated with C6-ceramide and examined for Akt 
dephosphorylation, PARP cleavage, and loss of viability. As shown in Fig. 4.23.A 
and B, ceramide treatment resulted in dose-dependent Akt dephosphorylation, 
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PARP cleavage, and loss of viability. Altogether, these results suggest that SNG 
mediates ROS-dependent ceramide generation, leading to Akt dephosphorylation 
and apoptosis in human leukemic cells. 
A       B 
 
Figure 4.23. Effect of ceramide on Akt phosphorylation status and apoptosis. Jurkat 
cells were treated with indicated concentration of C6-ceramide and (A) Western blot 
analysis for phospho-Akt Ser473, total Akt, and PARP was carried out. Actin was 
used as loading control and (B) cell viability was measured by using MTT assay. 
Data shown are means ± SD (n=3) (*p<0.05 and ***p<0.001 vs control). 
 
Two important serine/threonine phosphatases (PP1 and PP2A) allostericaly 
activated by ceramide, collectively termed as CAPP are shown to dephosphorylate 
Akt (Salinas et al., 2000; Schubert et al., 2000; Wolff, Dobrowsky, Bielawska, Obeid, 
& Hannun, 1994). To examine if any of these CAPPs are involved in SNG-induced 
Akt dephosphorylation, Jurkat cells were pre-treated with an increasing 
concentration of CalA (a well-established CAPP inhibitor) for 1 h followed by SNG 
treatment for 4 h. As shown in Fig. 4.24.A, CalA dose-dependently inhibited SNG-
induced Akt dephosphorylation. More importantly, CalA pre-treatment partially, but 
significantly, protected Jurkat cells from SNG-induced apoptosis and loss of viability 
(Fig. 4.24.A and B). These findings clearly indicate the involvement of CAPP in 
SNG-induced Akt dephosphorylation and apoptosis.  
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Figure 4.24. Sanguinarine induces Akt dephosphorylation via ceramide activated 
protein phosphatase. Jurkat cells were pre-treated with indicated concentrations of 
CalA for 1 h, followed by SNG treatment for 4 h. After the treatment, (A) Western 
blot analysis of phospho-Akt Ser473, total Akt, and PARP was performed. Actin was 
used as a loading control and (B) cell viability was measured by using MTT assay. 
Data shown are means ± SD (n=3) (*p<0.05, **p<0.01, and ***p<0.001).  
 
In order to distinguish between PP1 and PP2A involvement in SNG-induced 
apoptosis, another CAPP inhibitor with unique activity profile against CAPP was 
used. OA inhibits PP2A at low concentration (IC50< 0.1 nM), but it inhibits both PP2A 
and PP1 at higher concentration (IC50> 150 nM) (Thayyullathil, Chathoth, Shahin, et 
al., 2011). Jurkat cells were pre-treated with 1 nM and 300 nM OA, followed by 
treatment with SNG for 4 h. As shown in Fig. 4.25.A and B, OA at low concentration 
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(1 nM) did not affect SNG-induced Akt dephosphorylation, PARP cleavage, and loss 
of viability. However, at the higher concentration (300 nM), OA significantly blocked 
the SNG effect (Fig. 4.25.A and B). This activity profile strongly supports a role for 
PP1, but not PP2A in mediating SNG-induced Akt dephosphorylation. Indeed, this is 
further confirmed by using PA, a potent and selective inhibitor of PP1 (Kishikawa, 
Chalfant, Perry, Bielawska, & Hannun, 1999). Pre-treatment with PA significantly 
abolished SNG-induced Akt dephosphorylation, PARP cleavage and loss of viability 
(Fig. 4.25.C and D). Taken together, these results clearly indicate that SNG 
promotes Akt dephosphorylation and apoptosis via activating the PP1 form of 
CAPP. 
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Figure 4.25. Sanguinarine induces Akt dephosphorylation via protein phosphatase 1 
type of ceramide activated protein phosphatase. Jurkat cells were pre-treated with 
(A and B) indicated concentrations of OA, and (C and D) 30 µM PA for 1 h, followed 
by SNG treatment for 4 h. After the treatment, Western blot analysis for phospho-Akt 
Ser473, total Akt, and PARP was performed. Actin was used as a loading control. 
Cell viability was measured by using MTT assay. Data shown are means ± SD (n=3) 
(*p<0.05 and ***p<0.001).  
 
This was further validated by exposing Jurkat cells to CAPP inhibitors 
followed by treatment with C6-ceramide. As shown in Fig. 4.26.A, B and C, both 
CalA and PA protected the C6-ceramide-induced Akt dephosphorylation, while OA 
failed to do so. 
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Figure 4.26. Ceramide induces ceramide activated protein phosphatase-dependent 
Akt dephosphorylation. Jurkat cells were pre-treated with (A) CalA, (B) OA, and (C) 
PA, followed by C6-ceramide treatment. Western blot analysis for phospho-Akt 
Ser473 and total Akt was carried out. 
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4.5 Sanguinarine-induced apoptotic cell death is associated with reactive 
oxygen species-dependent activation of extracellular signal-regulated kinase 
1/2 in human leukemic cells. 
Mitogen activated protein kinases, including ERK1/2, JNK, and p38, are 
critical kinases that regulate a variety of biological process, such as cell survival, 
proliferation, differentiation, and apoptosis (Lu & Xu, 2006). Since these kinases are 
involved in the regulation of variety of proliferative and tumor suppressive signals, 
our fifth objective is to delineate the involvement of MAPKs in SNG-induced 
apoptosis. To determine the role of these kinases in SNG-induced loss of viability, 
leukemic cells were pre-treated with inhibitors of these kinases, and their influence 
on cell viability was evaluated following SNG treatment. As shown in Fig 4.27.A and 
B, pre-treatment with ERK1/2 inhibitor (U0126), significantly abrogated SNG-
induced loss of viability in both Jurkat (Fig 4.27.A) and Molt-4 (Fig 4.27.B) cells, 
while JNK inhibitor (SP600125) and p38 inhibitor (SB202190) had no effect on SNG-
induced loss of viability in both cells (Fig. 4.27.A and B). 
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Figure 4.27. Effect of mitogen activated protein kinase inhibitors on sanguinarine-
induced loss of viability. (A) Jurkat and (B) Molt-4 cells were pre-treated with U0126 
(30 µM), SP600125 (20 µM), and SB202190 (20 µM) for 1 h, followed by SNG 
treatment (3 μM for Jurkat and 1.5 μM for Molt-4) for 4 h. Cell viability was 
measured by using MTT assay. Data shown are means ± SD (n=3) (***p<0.001 and 
ns: not significant). 
The biological activity of ERK1/2 can be regulated via its phosphorylation 
(activation) and dephosphorylation (inactivation) status. To determine, if ERK1/2 is 
activated in response to SNG treatment, phosphorylation status of ERK1/2 was 
evaluated following SNG treatment. As shown in Fig. 4.28, treatment with SNG 
demonstrated an increase in ERK1/2 phosphorylation in both Jurkat and Molt-4 
cells. In Jurkat cells, maximum phosphorylation was seen at 30 min, while in Molt-4 
cells, phosphorylation gradually increased until 3 h (Fig. 4.28).  
 
 
 
 
Figure 4.28. Sanguinarine induces extracellular signal-regulated kinase 1/2 
phosphorylation in human leukemic cells. Jurkat cells were treated 3 µM and Molt-4 
cells were treated with 1.5 µM SNG for the indicated time period. Western blot 
analysis for phospho-ERK1/2, and total ERK1/2 was carried out. 
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In order to understand the biological significance of ERK1/2 phosphorylation 
in SNG-induced apoptosis, leukemic cells were pre-treated with ERK1/2 inhibitor 
U0126, prior to exposing the cells to SNG. Pre-treatment with U0126 not only 
inhibited SNG-induced ERK1/2 phosphorylation, but also decreased SNG-induced 
PARP cleavage in Jurkat (Fig. 4.29.A) and Molt-4 (Fig. 4.29.B) cells, demonstrating 
that ERK1/2 phosphorylation is involved in SNG-induced apoptosis. 
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Figure 4.29. Effect of extracellular signal-regulated kinase 1/2 inhibitor on 
sanguinarine-induced apoptosis. (A) Jurkat and (B) Molt-4 cells were pre-treated 
with U0126 (30 µM), followed by the SNG (3 µM for Jurkat and 1.5 µM for Molt-4 
cells) treatment. Western blot analysis for phospho-ERK1/2, total ERK1/2, and 
PARP was carried out. Actin was used as a loading control. 
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The intracellular generation of ROS has been shown to phosphorylate 
ERK1/2, and leads to the induction of apoptosis (X. Zhang et al., 2003). In addition, 
we have recently shown that SNG induces ROS-dependent ERK1/2 phosphorylation 
and subsequent induction of autophagic cell death in human malignant glioma cells 
(Pallichankandy et al., 2015) In order to examine if SNG-induced ERK1/2 
phosphorylation is downstream to ROS generation, cells pre-treated with ROS 
scavengers were treated with SNG, and examined for ERK1/2 phosphorylation 
status. Pre-treatment with GSH and NAC completely abrogated SNG-induced 
ERK1/2 phosphorylation (Fig. 4.30), demonstrating that ERK1/2 phosphorylation is a 
ROS-dependent process. 
 
 
 
 
 
 
Figure 4.30. Effect of reactive oxygen species scavengers on sanguinarine-induced 
extracellular signal-regulated kinase 1/2 phosphorylation. Cells were pre-treated 
with GSH (10 mM) and NAC (10 mM) for 1 h, followed by SNG (3 µM for Jurkat and 
1.5 µM for Molt-4 cells) treatment. Western blot analysis for phospho-ERK1/2, and 
total ERK1/2 was carried out. 
 
In order to examine if ERK1/2 activation is responsible for ceramide 
generation, intracellular ceramide generation was measured in leukemic cells pre-
treated with U0126, followed by SNG treatment. As show in Fig. 4.31, pre-treatment 
with U0126, had no effect on SNG-induced ceramide generation, demonstrating that 
ceramide generation is not regulated by ERK1/2. 
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Figure 4.31. Sanguinarine-induced ceramide generation is not regulated by 
extracellular signal-regulated kinase 1/2 activation. Cells were pre-treated with 
U0126 (30 μM), followed by the SNG (3 μM for Jurkat and 1.5 µM for Molt-4) 
treatment. Ceramide levels were measured as described in the Materials and 
methods. Data shown are means ± SD (n=3) (*p<0.05 and ns: not significant).  
 
Moreover, the possibility of ERK1/2 activation downstream to ceramide 
generation was also evaluated. Pre-treatment with aSMase inhibitor (Desip), did not 
inhibit SNG-induced ERK1/2 phosphorylation (Fig. 4.32), indicating that ERK1/2 
activation is not regulated by ceramide generation.  
 
 
 
 
 
Figure 4.32. Sanguinarine induced extracellular signal-regulated kinase 1/2 
activation is not regulated by ceramide generation. Jurkat cells were pre-treated with 
Desip (10 µM) for 1 h, followed by incubation with 3 μM SNG. Western blot analysis 
for phospho-ERK1/2 and total ERK1/2 was carried out. 
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In addition, pre-treatment with U0126, did not inhibit SNG-induced Akt 
dephosphorylation (Fig. 4.33), signifying that Akt dephosphorylation is not regulated 
by ERK1/2.  
 
 
 
 
 
 
Figure 4.33. Sanguinarine induces reactive oxygen species-dependent extracellular 
signal-regulated kinase 1/2 activation independent of the ceramide and Akt pathway. 
Cells were pre-treated with U0126 (30 μM), followed by the SNG (3 μM for Jurkat 
and 2 µM for Molt-4) treatment. Western blot analysis for phospho-Akt Ser473 and 
total Akt was carried out. 
 
Taken together, these findings clearly indicate that ERK1/2 activation is not 
downstream to ceramide generation and both ceramide generation and Akt 
dephosphorylation is not regulated by ERK1/2. 
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Chapter 5: Discussion and conclusion 
 
The present study investigated the antileukemic potential of SNG in vitro and 
further examined the molecular signaling mechanisms involved in this process. The 
results from this study demonstrate that SNG exhibits a potent pro-apoptotic effect 
on leukemic cells via two different mechanisms. In the first mechanism, SNG 
induces excessive ROS generation, leading to ceramide accumulation, which further 
mediates the inhibition of Akt signaling pathway, and activation of the caspase 
cascade. In the second mechanism, SNG mediates ROS-dependent ERK1/2 
activation, leading to the induction of apoptosis. In recent studies, SNG has been 
shown to induce apoptosis in many cancer cells such as skin (Hammerová et al., 
2011; Rosen et al., 2015), breast (Dong et al., 2013; S. Kim et al., 2008), lung (S. 
Gu et al., 2015; Jang et al., 2009), bladder (Han, Park, et al., 2013), prostate 
(Adhami et al., 2004), cervix (Xu et al., 2012), as well as, primary effusion lymphoma 
(Hussain et al., 2007) through the activation of diverse signaling mechanisms, 
including ROS generation and ER stress, as well as inhibition of NFκB (Chaturvedi 
et al., 1997; Duvoix et al., 2004; S. Gu et al., 2015; Hussain et al., 2007; S. Kim et 
al., 2008; Matkar et al., 2008a; S. Y. Park et al., 2014; Xu et al., 2012; Yin et al., 
2005). However, none of these studies explored the functional role of ROS-
ceramide-Akt signaling axis in SNG-induced tumor suppression. This is the first 
study demonstrating that SNG mediates caspase activation and apoptosis in human 
leukemic cells via ROS-dependent ceramide accumulation and inactivation of Akt 
signaling pathway (Fig. 5.1). Furthermore, our study also demonstrates involvement 
of ROS-dependent ERK1/2 phosphorylation in SNG-induced apoptosis (Fig. 5.1). In 
particular, the demonstration that SNG induces ceramide accumulation is extremely 
important, since ceramide plays a critical role in the activation and execution of 
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various signal transduction pathways, leading to tumor suppression (Galadari et al., 
2015).  
 
Figure 5.1. Proposed mechanism of sanguinarine-induced apoptosis in human 
leukemic cells. SNG induces ROS-dependent ceramide up-regulation, which in turn 
activates CAPP (PP1), leading to Akt dephosphorylation and subsequent induction 
of caspase-dependent apoptosis in human leukemic cells. Alternatively, SNG 
induces ROS-dependent ERK1/2 activation, leading to the induction of apoptosis. 
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Micromolar concentration of SNG has been shown to impart apoptosis in 
A431 human squamous carcinoma cells, but not in normal human epidermal 
keratinocytes at similar concentrations (Ahmad et al., 2000). Differential toxicity of 
SNG was also observed by Kaminskyy et al, where DNA damaging effects of SNG 
was more selective towards mouse leukemic cells compared to primary mouse 
spleen cells (Kaminskyy, Lin, et al., 2008). Sun et al. also observed profound 
cytotoxicity of SNG in DU145 and C4-2 prostate cancer cells compared to PZ-HPV7 
normal prostate epithelial cells (Sun et al., 2010). On the other hand, others have 
shown that SNG does not exhibit more sensitivity against cancer cells versus normal 
cells (Debiton et al., 2003; Malíková et al., 2006; Slunská et al., 2010). Knowing that 
ROS generation is one of its prime signaling mechanisms, it is possible that SNG is 
more selective towards tumor cells as opposed to normal cells. Cancer cells have 
elevated basic ROS level compared to normal cells. It can be therapeutically utilized 
by further increasing ROS generation to such a toxic level which may specifically 
induce death in cancer cells (Fig. 5.2).  
 
 
 
 
 
 
 
 
 
Figure 5.2. ROS levels in normal versus cancer cells. Cancer cells have elevated 
basal ROS levels as opposed to normal cells. Treatment with anticancer agents may 
increase ROS generation in cancer cells above the death threshold and induce 
death specifically in cancer cells, but not in normal cells. 
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In line with this, Leung et al. demonstrated that tyrosine kinase inhibitor-
resistant non-small cell lung cancer (with T790M mutation in EGFR) have increased 
NOX2 activity and substantially higher basal ROS levels compared to normal lung 
tissues (Leung et al., 2015). SNG was shown to induce NOX3 activity in EGFR 
mutant cells, leading to EGFR over-oxidation, degradation and apoptosis (Leung et 
al., 2015). Such response were not observed in EGFR wild-type cells, 
demonstrating that ROS generation may be one of the key factors that determine 
the tumor selectivity of SNG; however, this needs to be further investigated. 
ROS-mediated cytotoxicity may be achieved by using agents that either 
increase ROS generation, or inhibit antioxidant defense, or a combination of both. 
Thus, use of a compound that causes further increases in intracellular ROS, in 
conjunction with inhibitors of antioxidant system, might be a promising approach 
towards developing more successful anticancer therapy. For instance, a 
combination of arsenic trioxide (a ROS-generating agent) and 2-methoxyestradiol (a 
SOD inhibitor) were demonstrated to have synergistic activity against human 
leukemia (Y. Zhou, Hileman, Plunkett, Keating, & Huang, 2003). In this context, 
SNG is a ‘multifaceted ligand’, where it induces both ROS generation and diminution 
of the cellular antioxidant system (GSH and catalase). We show several lines of 
evidence that demonstrate the vital involvement of ROS in SNG-induced apoptotic 
cell death. First, SNG induces a dose-dependent ROS production (Fig. 4.6.A and B). 
Second, pre-treatment of cells with ROS scavengers (GSH and NAC) almost 
completely abolished SNG-induced ROS production and apoptosis (Fig. 4.7.A, B, C 
and D). Third, the cytotoxic effect of SNG was significantly abolished in the 
presence of a variety of antioxidants (Fig. 4.7.E). In particular, our results 
demonstrate that SNG-induced apoptosis was mediated, at least in part, by an 
increase in the cellular levels of H2O2, as evidenced by the attenuation of ROS-
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derived fluorescence and loss of viability following pre-treatment with H2O2-specific 
scavengers (Fig. 4.8.A, B, and C and Fig. 4.9).  
The present study also underscores involvement of the tumor suppressor 
lipid ceramide downstream to ROS in SNG-induced apoptosis. It is now well-
established that ceramide modulates diverse intracellular signaling pathways that 
increase the sensitivity of human tumor cells to various anticancer agents (Galadari 
et al., 2015). Furthermore, defects in ceramide generation and metabolism could 
potentially contribute to the tumor cell survival and resistance to chemo and 
radiotherapy (Galadari et al., 2015). In the present study, we validate that SNG 
induces ROS-dependent ceramide generation (Fig. 4.13.A and B), and also 
demonstrate that increased ceramide generation plays a functional role in SNG-
induced apoptosis (Fig. 4.15.E and Fig. 4.16.D). It is noteworthy that ROS 
production is required for the accumulation of ceramide in response to SNG-
treatment. A direct link between ROS and ceramide production has been 
established in several cancer cell lines including leukemia (Gouazé et al., 2001; 
Mansat-de Mas et al., 1999). We also demonstrate that extracellular 
supplementation of antioxidants to human leukemic cells inhibited SNG-induced 
ceramide production (Fig. 4.13.A and B).  
Most of the anticancer agents which induce endogenous ceramide 
generation act by interfering with the enzymes of ceramide biosynthetic or 
degradative pathway. Ceramide accumulation mainly occurs via (1) de novo 
pathway, (2) SMase-mediated hydrolysis of sphingomyelin, and (3) inhibition of 
CDase- or GCS-mediated conversion of ceramide into sphingosine and 
glucosylceramide, respectively. In the present study, SNG was shown to induce the 
activity of aSMase in Jurkat cells (Fig. 4.15.I), while inhibiting the activity of both 
aCDase and GCS in both Jurkat and Molt-4 cells (Fig. 4.16.A and B). No significant 
increase in aSMase activity was observed in Molt-4 cells (Fig. 4.15.I), which are 
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inherently known for having very little aSMase activity (B. Liu & Hannun, 1997). It is 
noteworthy that GCS inhibition by SNG was significant and occurred within 1 h of 
SNG treatment in both cell lines (Fig. 4.16.A and B). Mechanism of SNG-induced 
GCS inhibition needs further investigation. Such studies are underway in our 
laboratory. The involvement of ceramide biosynthetic and degradative enzymes in 
SNG-induced apoptosis was further confirmed by using various inhibitors that 
manipulate the activities of these enzymes. Pre-treatment with aSMase inhibitor 
(Desip) resulted in the attenuation of both ceramide generation and apoptosis (Fig. 
4.15.C, D and E), while, the aCDase inhibitor (NOE) and GCS inhibitor (PDMP) 
promoted it (Fig. 4.16.C, D and E). The manipulation of ceramide biosynthetic 
enzymes by anticancer agents have also been reported previously. Several pro-
apoptotic stimuli, such as FAS, TNF-α, and UV irradiation activate aSMase-
mediated ceramide generation in a variety of cancer cell types to induce apoptosis 
(Gulbins & Grassmé, 2002; Y. Zhang et al., 2001). Similarly, tamoxifen inhibits 
ceramide glucosylation (mediated by GCS), leading to the accumulation of 
intracellular ceramide and induction of apoptosis in adriamycin-resistant MCF-7 
human breast cancer cells (Lavie et al., 1997). Moreover, inhibition of aCDase was 
found to be essential for the anticancer activity of Carmofur, a clinically used 
antineoplastic drug for the treatment of colorectal carcinoma (Realini et al., 2013). 
In this context, our results show that SNG induces ROS-dependent intracellular 
accumulation of ceramide via activation of aSMase (in Jurkat) and inhibition of GCS 
and aCDase (in Jurkat and Molt-4), and induces apoptosis, supporting a significant 
role for ceramide in triggering apoptosis.  
Akt is crucial to many aspects of cell growth, survival and apoptosis, and is 
frequently activated in many cancers including leukemia (Chang et al., 2003; 
Fransecky et al., 2015; Manning & Cantley, 2007). Akt activation in turn signals a 
variety of key downstream targets, including GSK3β and mTOR, which 
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consequently inhibit apoptosis and promote cell survival (Manning & Cantley, 2007). 
Previously, others have shown that inhibition of Akt signaling pathway is consistently 
associated with the induction of apoptosis in cancer cells (K. F. Chen et al., 2008; 
Hennessy, Smith, Ram, Lu, & Mills, 2005; Manning & Cantley, 2007). Our results 
show that SNG inhibits Akt phosphorylation at Ser473 (Fig. 4.18.A and B). The 
inhibitory effect of SNG on Akt phosphorylation is also correlated with the 
dephosphorylation of its downstream targets, GSK3β and mTOR (Fig. 4.20). It is 
well established that mTOR itself is an important cell growth and pro-survival protein 
that is activated by Akt-mediated phosphorylation at Ser2448, whereas, GSK3β 
mainly acts as a pro-apoptotic protein that is inactivated by Akt-mediated Ser9 
phosphorylation (Ciuffreda et al., 2010; Jacobs et al., 2012; Manning & Cantley, 
2007; Pópulo et al., 2012). SNG-mediated dephosphorylation of Akt may reactivate 
the tumor suppressive functions of GSK3β, while inactivating the pro-tumorigenic 
functions of mTOR. In addition, SNG treatment has also been shown to reduce the 
phosphorylation status of the mTOR downstream target, 4EBP1 (Fig. 4.20). A 
plethora of studies have demonstrated the link between ceramide and Akt in the 
regulation of apoptosis (Salinas et al., 2000; Schubert et al., 2000). Several studies 
have demonstrated that CAPPs (PP1 and PP2A) dephosphorylate Akt at Ser473 
and induce apoptosis (Salinas et al., 2000; Schubert et al., 2000). This effect was 
reversed by pre-treatment with CAPP inhibitors such as CalA and OA (Salinas et al., 
2000; Schubert et al., 2000). In our study, Akt dephosphorylation did not initiate until 
there was significant ceramide generation, suggesting the possible involvement of 
CAPPs in SNG-induced Akt dephosphorylation. Moreover, in this study, several 
lines of evidence demonstrate the vital involvement of ceramide in SNG-induced Akt 
dephosphorylation. First, aSMase inhibitor (Desip) significantly blocked SNG-
induced Akt dephosphorylation and apoptosis (Fig. 4.15.E and 4.22.A). Second, 
enhancement of ceramide generation using aCDase inhibitor (NOE) and GCS 
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inhibitor (PDMP) sensitized SNG-induced Akt dephosphorylation and apoptosis (Fig. 
4.16.D and 4.22.C). Third, direct treatment of leukemic cells with C6-ceramide 
resulted in Akt dephosphorylation (Fig. 4.23.A). Forth, using various CAPPs 
inhibitors (CalA, OA, and PA), it was clearly demonstrated that activation of the PP1 
form of CAPP was responsible for SNG-induced Akt dephosphorylation (Fig. 4.24.A 
and B and Fig. 4.25.A, B, C and D). In addition, ROS scavengers such as GSH and 
NAC also significantly abolished SNG-induced Akt dephosphorylation, 
demonstrating the role of ROS in Akt dephosphorylation (Fig. 4.21). Thus, these 
results clearly demonstrate that SNG induces ROS-dependent ceramide generation, 
which in turn activates PP1, leading to Akt dephosphorylation and apoptosis in 
human leukemic cells (Fig. 5.1).  
Importantly, our study has also identified a crucial role of ERK1/2 in the 
facilitation of SNG-induced apoptotic cell death. Antioxidants, such as GSH and 
NAC, significantly abrogated ROS production and ERK1/2 activation, demonstrating 
the key role of ROS in ERK1/2 activation. Using ERK1/2 inhibitor (U0126), we 
identified that neither ceramide generation nor Akt dephosphorylation are regulated 
by ERK1/2. Moreover, ceramide inhibitor (Desip) did not attenuate ERK1/2 
activation, demonstrating that ERK1/2 follows an alternative pathway of cell death, 
independent of ceramide-Akt axis. The mechanism involved in the ERK1/2-mediated 
apoptosis by SNG needs further investigation.  
In summary, our study demonstrates that a hierarchy of signaling events are 
activated by SNG in order to induce apoptosis in human leukemic cells. Briefly, SNG 
induces caspase-dependent apoptosis in human leukemic cells, which is regulated 
by ROS-dependent ceramide up-regulation, which in turn activates PP1, leading to 
Akt dephosphorylation (Fig. 5.1). In an alternative pathway, SNG induces ROS-
dependent ERK1/2 activation, leading to the induction of apoptosis in human 
leukemic cells (Fig. 5.1). Further investigations to understand the mechanisms by 
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which SNG induces apoptosis in human leukemic cells, tumor xenografts, and 
leukemic mice models should provide a rationale for the application of SNG-based 
pro-apoptotic drug in the treatment of leukemia. Accordingly, such studies are 
currently underway in our laboratory. 
 
In conclusion, our data demonstrate that SNG induces: 
 Caspase-dependent apoptosis in human leukemic cells. 
 Mitochondrial H2O2 generation and subsequent induction of apoptosis in 
human leukemic cells. 
 ROS-dependent ceramide generation via aSMase activation (in Jurkat cells) 
and aCDase and GCS inhibition (in Jurkat and Molt-4 cells). 
 Ceramide-dependent PP1 activation and subsequent induction of Akt 
dephosphorylation at Ser473 in human leukemic cells. 
 ROS-dependent ERK1/2 activation, leading to the induction of apoptosis 
independent of the ceramide activation and Akt dephosphorylation. 
This conclusion is illustrated pictorially in Fig. 5.1. 
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Chapter 6: Future directions 
 
Three independent findings by Ahmad et al., Kaminskyy et al., and Sun et 
at., demonstrate that cytotoxicity of SNG is more selective against cancer cells 
compared to normal cells (Ahmad et al., 2000; Kaminskyy, Lin, et al., 2008; Sun et 
al., 2010). In contrast, others have shown that SNG does not exhibit preferential 
sensitivity against cancer cells versus normal cells (Debiton et al., 2003; Malíková et 
al., 2006; Slunská et al., 2010). In future experiments, by using variety of normal and 
cancer cells, we will evaluate whether SNG exhibits any kind of selectivity against 
cancer cells. Two possible explanation can be drawn for preferential sensitivity of 
SNG against cancer cells:   
(1) In our study, we have shown that SNG induces ROS generation which is critical 
for the induction of apoptosis. Furthermore, several previous reports have provided 
strong evidence for the involvement of ROS in the facilitation of SNG-induced 
apoptosis (Dong et al., 2013; S. Kim et al., 2008; Matkar et al., 2008a, 2008b; Yin, 
Kim, Moon, & Lee, 2005). Knowing that cancer cells already have increased basal 
ROS level, SNG-induced ROS generation may further intensify intracellular ROS 
levels in cancer cells to such a toxic level, which may specifically induce death in 
cancer cells (Fig. 5.2).  
(2) We have identified that SNG induces expression and activation of tumor 
suppressor protein, prostate apoptosis response-4 (Par-4) in Jurkat cells (data not 
shown). Par-4 is known to selectively activate and induce apoptosis in cancer cells, 
but not in normal cells (Thayyullathil et al., 2014). In future, we will evaluate whether 
ROS generation or Par-4 activation is involved in the SNG-induced tumor selectivity.  
 In the present study, we identified that SNG induces rapid and significant 
inhibition of GCS enzyme in both Jurkat and Molt-4 cells. Similar results were also 
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observed in PC-3 and DU145 prostate cancer cells (data not shown). However, it 
has not been studied as to how GCS enzyme activity is inhibited by SNG. The 
mechanism(s) involved in this process will be evaluated in future experiments by 
employing suitable in vivo and in vitro models. Additionally, a plethora of studies 
demonstrate that, as opposed to conventional chemotherapeutic agents, SNG is 
effective against various multidrug resistant cancer cells overexpressing P-gp 
protein (Ding et al., 2002; Eid et al., 2013; Gatti et al., 2014; Weerasinghe et al., 
2006). It is noteworthy that GCS activity is very well associated with P-gp expression 
and resistance to chemotherapy (Gouazé et al., 2005; Gouazé et al., 2004; Gupta & 
Liu, 2013; Lavie, Cao, Bursten, Giuliano, & Cabot, 1996; Y. Y. Liu et al., 2010; Y. Y. 
Liu, Han, Giuliano, & Cabot, 1999; Y. Y. Liu, Han, Giuliano, Hansen, & Cabot, 2000; 
Y. Y. Liu, Hill, & Li, 2013; Lucci et al., 1998). In future, we would like to examine 
whether increased sensitivity of SNG against P-gp overexpressing multidrug 
resistant cancer cells is mediated via its GCS inhibitory activity. 
 In this study, we have identified that SNG-induces ROS-dependent ERK1/2 
phosphorylation leading to the induction of apoptosis in human leukemic cells. 
Previously, we have also identified that SNG-induces ROS-dependent ERK1/2 
phosphorylation, leading to the induction of autophagic cell death in human 
malignant glioma cells (Pallichankandy et al., 2015). The mechanism by which SNG 
regulates ERK1/2 activity requires further investigation. The upstream and 
downstream regulators in this process will be studied in future.  
Further investigation to understand the mechanisms by which SNG induces 
apoptosis in human leukemia cells using tumor xenografts will provide a rationale for 
the application of SNG-based pro-apoptotic drug in the treatment of leukemia. 
Accordingly, such studies are currently underway in our laboratory. 
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